American Association for Cancer Research Annual...

1

American Association for Cancer Research Annual Meeting

UCSF

HEL

EN D

ILLE

R F

AM

ILY

COM

PREH

ENSI

VE C

ANCE

R CE

NTER

April 14-18, 2018 Chicago, IL UCSF Presentation Brochure

1

For the past three years, it has been my privilege to work with UCSF’s team of exceptional cancer scientists who are helping to transform cancer into a manageable disease, and hopefully one day, a curable disease. Among our many programs, UCSF faculty are driving efforts to overcome drug resistance, a key limitation of targeted therapy; developing drugs against previously undruggable proteins; and making significant advances in cryo-electron microscopy that is allowing scientists to visualize a broad spectrum of proteins at resolutions approaching crystal structure resolutions. We are leading the way on the next generation of cellular therapies, with novel approaches to addressing specificity and efficacy, while minimizing side effects. Also, we’ve expanded our state-of-the-art cancer imaging program to more rapidly assess disease progression and treatment response, creating time to move patients to other therapies when first-line therapies fail. All of us are working in an exciting new era of collaboration. We recognize that bringing advancements to patients is best accomplished by working in partnership with the broader life science industry. As an NCI-designated comprehensive cancer center, UCSF is recognized for our outstanding science, extensive resources, depth and breadth of our research in basic, clinical, and population sciences, as well as cutting edge research that bridges these scientific areas. UCSF is home to many of the world’s finest oncology clinicians and scientists who understand the power of partnerships. This searchable abstract book of UCSF research presented at AACR is a resource for potential partners interested in identifying world-class faculty engaged in basic science and clinical oncology research. I invite you to learn more about our work and expertise by reaching out to our faculty during this meeting. If you have additional questions or would like assistance with your outreach, please contact the Director of Strategic Alliances for the Cancer Center: Cammie Edwards ( ). I wish you a very productive meeting, and we look forward to future discussions and collaborations.

Alan Ashworth, PhD, FRS

EXCEPTIONAL PEOPLE EXTRAORDINARY SCIENCE

Alan Ashworth, PhD, FRS

President, UCSF Helen Diller Family Comprehensive Cancer Center

Senior Vice President for Cancer Services,UCSF Health

Professor of Medicine, Division of Hematology/Oncology, Department of Medicine

2

OUR SUCCESS IS DRIVEN BY OUR FACULTYHDFCCC Membership: 453 Members & Affiliate Members

2 Nobel Laureates3 Albert Lasker Award winners8 Howard Hughes Medical Investigators16 Members of the National Academy of Sciences20 Members of the Institute of Medicine22 Fellows of the American Academy of Arts and Sciences6 Fellows of the Royal Society

3

UCSF IN THE NEWS (Click on link to read story)

New Approach Attacks ‘Undruggable’ Cancers from the Outside In: Antibodies Target Cell Surface Proteins Produced by Ras Mutationscancer.ucsf.edu/news/2018/01/23/new-approach-attacks-undruggable-cancers-from-the-outside-in.8739

Engineers Hack Cell Biology to Create 3-D Shapes from Living Tissuecancer.ucsf.edu/news/2017/12/28/engineers-hack-cell-biology-to-create-3-d-shapes-from-living-tissue.8703

DNA Annotations Predict Patient Outcomes in Childhood Leukemia: An Epigenetic Biomarker May Identify which Children with a Rare Blood Cancer will Benefit from Minimal Therapiescancer.ucsf.edu/news/2017/12/19/dna-annotations-predict-patient-outcomes-in-childhood-leukemia.8701

Collaboration Highlights UCSF Cancer Center’s Leadership in Precision Medicine for Prostate Cancercancer.ucsf.edu/news/2017/12/11/collaboration-highlights-ucsf-cancer-centers-leadership-in-precision-medicine-for-prostate-cancer.8651

New Immunotherapy for Deadly Childhood Brain Cancer Targets Novel “Neoantigen”: UCSF Research Leads to a Clinical Trial of New Cancer Vaccine and Development of Cell Therapy Approachescancer.ucsf.edu/news/2017/12/04/new-immunotherapy-for-deadly-childhood-brain-cancer-targets-novel-neoantigen.8664

Cell Mapping Initiatives Aim to Uncover Hidden Pathways of Disease:The Projects are Exploring Common Biology of Cancer, Infection and Psychiatric Diseasecancer.ucsf.edu/news/2017/11/15/cell-mapping-initiatives-aim-to-uncover-hidden-pathways-of-disease.8626

Deadly Lung Cancers are Driven by Multiple Genetic Changes: Blood-Based Cancer Tests Reveal Complex Genomic Landscape of Non-Small Cell Lung Cancerscancer.ucsf.edu/news/2017/11/06/deadly-lung-cancers-are-driven-by-multiple-genetic-changes.8606

UCSF’s Cryo-Electron Microscopy Advancements Bring Atomic-Level Life into Clearer View: Researchers Are Pushing the Boundaries of Nobel-Winning Technology to Better Understand Human Healthcancer.ucsf.edu/news/2017/10/26/ucsfs-cryo-electron-microscopy-advancements-bring-atomic-level-life-into-clearer-view.8599

Cancer-Killing Virus Acts by Alerting Immune System: Vaccine-like Effect Suggests Potential for Combination With Cancer Immunotherapyhttps://www.ucsf.edu/news/2018/02/409851/cancer-killing-virus-acts-alerting-immune-system

Gilead Sciences and Kite to Acquire Cell Design Labs, One of UCSF Startups for up to $567MMhttps://ita.ucsf.edu/news-and-events/gilead-sciences-and-kite-acquire-cell-design-labs-one-ucsf-startups-567-mm

UCSF and Parker Institute for Cancer Immunotherapy Scientist Kole Roybal Wins Inaugural Sartorius & Science Prize for Regenerative Medicine & Cell Therapyhttps://www.parkerici.org/2018/03/08/parker-institute-for-cancer-immunotherapy-scientist-kole-roybal-of-ucsf-wins-inaugural-sartorius-science-prize-for-regenerative-medicine-cell-therapy-2/

http://cancer.ucsf.edu/news/2018/01/23/new-approach-attacks-undruggable-cancers-from-the-outside-in.8739



http://cancer.ucsf.edu/news/2017/12/28/engineers-hack-cell-biology-to-create-3-d-shapes-from-living-tissue.8703




http://cancer.ucsf.edu/news/2017/12/19/dna-annotations-predict-patient-outcomes-in-childhood-leukemia.8701



http://cancer.ucsf.edu/news/2017/12/11/collaboration-highlights-ucsf-cancer-centers-leadership-in-precision-medicine-for-prostate-cancer.8651



http://cancer.ucsf.edu/news/2017/12/04/new-immunotherapy-for-deadly-childhood-brain-cancer-targets-novel-neoantigen.8664



http://cancer.ucsf.edu/news/2017/11/15/cell-mapping-initiatives-aim-to-uncover-hidden-pathways-of-disease.8626



http://cancer.ucsf.edu/news/2017/11/06/deadly-lung-cancers-are-driven-by-multiple-genetic-changes.8606



http://cancer.ucsf.edu/news/2017/10/26/ucsfs-cryo-electron-microscopy-advancements-bring-atomic-level-life-into-clearer-view.8599



https://www.ucsf.edu/news/2018/02/409851/cancer-killing-virus-acts-alerting-immune-system



https://ita.ucsf.edu/news-and-events/gilead-sciences-and-kite-acquire-cell-design-labs-one-ucsf-startups-567-mm



https://www.parkerici.org/2018/03/08/parker-institute-for-cancer-immunotherapy-scientist-kole-roybal-of-ucsf-wins-inaugural-sartorius-science-prize-for-regenerative-medicine-cell-therapy-2/



4

TRANSLATING LABORATORY DISCOVERIES INTO IMPROVED PATIENT CAREWhether it is advancing a new vaccine based immunotherapy, developing a new diagnostic test to

distinguish benign moles from malignant melanoma, or pioneering new adaptive clinical trial designs,

UCSF’s success in translating laboratory discoveries into improved patient care comes from its faculty

and culture of exploration and collaboration. With over 400 faculty relentlessly pursuing oncology

research and clinical practice, we continue to make significant strides in understanding the biology of

disease and improving patient outcomes with advanced clinical care.

WORKING TOGETHER ADVANCING THE UNDERSTANDING AND TREATMENT OF CANCER

NCI - Supported Research Programs (click on link to get more information)

Additional Cancer Research (click on link to get more information)

Key Initiatives (click on link to get more information)

• Cancer Risk

• Gastrointestinal Oncology

• Gynecologic Oncology

• Melanoma

• Multiple Myeloma

• Pancreas Cancer

• Pediatric Brain Tumor Research

• Thoracic Oncology

• Cancer Immunotherapy

• Center for BRCA Research

• Global Cancer

• Molecular Oncology

• Precision Cancer Medicine Building

• The San Francisco Cancer Initiative (SF CAN)

• UC Cancer Centers Consortium

• Breast Oncology

• Cancer Control

• Cancer Genetics

• Cancer Immunology

• Experimental Therapeutics

• Hematopoietic Malignancies

• Neurologic Oncology

• Pediatric Malignancies

• Prostate Cancer

• Tobacco Control

http://cancer.ucsf.edu/research/cancer-risk

http://cancer.ucsf.edu/gi/

https://obgyn.ucsf.edu/gynecologic-oncology/gynecologic-oncology-research

http://cancer.ucsf.edu/research/melanoma/

http://cancer.ucsf.edu/research/multiple-myeloma/mmti/

http://cancer.ucsf.edu/research/pancreas/

http://neurosurgery.ucsf.edu/index.php/research_pediatric.html

https://top.ucsf.edu/

http://cancer.ucsf.edu/support/immunotherapy/

http://brca.ucsf.edu/

https://globalcancer.ucsf.edu/

http://cancer.ucsf.edu/research/molecular-oncology/

http://cancer.ucsf.edu/about/pcmb

http://www.sfcancer.org/

http://cancer.ucsf.edu/research/programs/breast/

http://cancer.ucsf.edu/research/programs/cancer-control/

http://cancer.ucsf.edu/research/programs/genetics

http://cancer.ucsf.edu/research/programs/cancer-immunology

http://cancer.ucsf.edu/research/programs/therapeutics

http://cancer.ucsf.edu/research/programs/hematopoietic-malignancies

http://cancer.ucsf.edu/research/programs/neuro

http://cancer.ucsf.edu/research/programs/pediatric-malignancies

http://cancer.ucsf.edu/research/programs/prostate

http://cancer.ucsf.edu/research/programs/tobacco

5

CORE CAPABILITIES SUPPORTING OUR PROGRAMS

Biorepository and Tissue Biomarker TechnologyProvides optimal acquisition, processing, and storage of human tissue biospecimens, as well as state-of-the-art biomarker histologic detection and/or image analyses for both human and mouse tissue biospecimens.

BiostatisticsProvides statistical expertise and collaboration to the UCSF cancer research community on all phases of basic science, translational, clinical, epidemiological, and prevention research.

Cancer Imaging ResearchProvides technical capabilities and scientific expertise for integrating cutting-edge, multi-modality imaging into basic, translational, and clinical research.

Computational Biology and InformaticsProvides computational biology and computational infrastructure support to the UCSF cancer research community.

Laboratory for Cell AnalysisProvides cytometric, microscopic, and genomic support and services for the UCSF cancer research community.

Preclinical TherapeuticsOffers a complete set of preclinical services and in vivo imaging devices for cancer investigators.

Small Molecule DiscoveryCollaborates with academics, government labs, and pharmaceutical companies to develop unique chemical probes and drug leads that address unmet medical needs in cancer.

Tobacco BiomarkersServes as an analytical chemistry resource for the UCSF tobacco control and cancer research community.

http://cancer.ucsf.edu/research/cores/tissue/

http://cancer.ucsf.edu/research/cores/biostatistics

http://cancer.ucsf.edu/research/cores/imaging

http://cbi.ucsf.edu/

http://cancer.ucsf.edu/research/cores/lca

http://cancer.ucsf.edu/research/cores/preclinical/

http://cancer.ucsf.edu/research/cores/small-molecule/

http://cancer.ucsf.edu/research/cores/tobacco-biomarkers

6 *UCSF authors in bold

SATURDAY | APRIL 14, 2018

Assessing the shared genetic basis of different cancers

Authors*: John S. Witte

Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/9644 Presentation Date/Time: April 14, 2018, 10:15 AM - 10:40 AMLocation: Room N228 - McCormick Place North (Level 2)Presentation: Educational Session

Witte Research Interests: Our research program encompasses a synthesis of methodological and applied genetic epidemiology, with the overall aim of deciphering the mechanisms underlying complex diseases and traits (Witte, Visscher & Wray, Nature Reviews Genetics 2014). Our methods work is focused on the design and statistical analysis of next-generation sequencing and genetic association studies. We are applying these methods to studies of cancer (e.g., of the prostate), birth defects, and pharmacogenomics.

http://wittelab.ucsf.edu/pages/research

_______________________________________________________________________

Colorectal cancer early diagnosis in low and middle income countries

Authors*: Katherine Van Loon

Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/10932Presentation Date/Time: April 14, 2018, 1:50 PM - 2:20 PMLocation: Room S106 - McCormick Place South (Level 1)Presentation: Educational Session

Van Loon Research Interests: Dr. Van Loon is a gastrointestinal oncologist. Her research is focused on understanding the disproportionately high incidence of esophageal cancer in East Africa, and she is a founding member of the African Esophageal Cancer Consortium (AfrECC). In collaboration with Muhimbili University of Health and Allied Sciences and Ocean Road Cancer Institute in Tanzania, she is the Principal Investigator of several studies to identify environmental exposures and genetic and molecular determinants of esophageal squamous cell carcinoma along the eastern corridor of Africa. In her role as Director of the Global Cancer Program at UCSF’s Helen Diller Family Comprehensive Cancer Center, she oversees a large portfolio of research and capacity-building projects in low and middle-income countries and is focused on providing research training and mentoring to early career investigators with interests in the emerging academic field of global oncology.

http://cancer.ucsf.edu/gi/katherine-van-loon

_______________________________________________________________________

PRESENTATIONS*UCSF authors in bold

SU

ND

AY

|

AP

RIL

15

, 2

018


Translating the cancer genome one codon at a time

and its therapeutic implications

Authors*: Davide Ruggero

Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/1166 Presentation Date/Time: April 14, 2018, 2:00 PM - 2:25 PMLocation: Room S504 - McCormick Place South (Level 5)Presentation: Educational Session

_______________________________________________________________________

SUNDAY | APRIL 15, 2018

Accelerating the Pace of Change by Incorporating Early End Point Into Care and Trials

Authors*: Laura J. Esserman

Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/6902Presentation Date/Time: April 15, 2018, 7:00 AM - 8:00 AMLocation: Room S103 - McCormick Place South (Level 1)Presentation: Meet-the-Expert Session

Esserman Research Interests: Dr. Esserman, surgeon & breast cancer oncology specialist, is the Carol Franc Buck Breast Care Center Director and co-leads the Breast Oncology Program. Her research is on improving healthcare value through integrating translational science, clinical informatics, systems re-engineering & clinical care delivery. In 2005, she received the NCI SPORE Investigator of the Year Award. In 2016 she received the Arbuckle Award from Stanford Graduate School of Business for Excellence in Management & was named to TIME’s 100 most influential people list. She is PI of the I-SPY TRIAL program, now a model for translational research & innovation in clinical trial design. She launched the Athena Breast Health Network to follow women from screening through treatment & outcomes, incorporating the latest in molecular testing & web-based tools. Athena just launched the WISDOM study to compare personalized vs annual breast cancer screening in 100,000 women and to predict who gets what kind of cancer.

http://profiles.ucsf.edu/laura.esserman

_______________________________________________________________________

SU

ND

AY

|

AP

RIL

15

, 2

018


“Ethnicity,” nationality, genetic ancestry and breast cancer in women of Latin American origins

Authors*: Laura Fejerman

Abstract #:Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/307Presentation Date/Time: April 15, 2018, 1:00 PM - 1:25 PMLocation: Room N427 - McCormick Place North (Level 4)Presentation: Recent Advances in Cancer Health Disparities Research

Fejerman Research Interests: Dr. Fejerman focuses on the discovery of genetic and non-genetic factors that contribute to breast cancer risk and prognosis in Latinas. Her past work established a relationship between genetic ancestry and breast cancer risk, where higher European ancestry in U.S. and Mexican Latinas was associated with an increased risk. Her subsequent research has built upon this observation, exploring genetic variants, through admixture mapping and genome-wide association approaches, as well as the possible environmental and lifestyle related factors, and ancestry-gene interactions. Recent work explores disparities in breast cancer prognosis by genetic ancestry in Latinas and its potential causes.

http://fejerman.ucsf.edu

_______________________________________________________________________

Tumor suppression by regulator of asymmetric cell division in glioma

Authors*: Mathieu Daynac, Malek Chouchane, Alex Valenzuela, Claudia K. Petritsch

Abstract #:149Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/6108Presentation Date/Time: April 15, 2018, 1:00 PM - 5:00 PMLocation: Section 6Presentation: Poster Session

Petritsch Research Interests: The Petritsch Lab uses pharmacological, molecular, and in vivo and ex vivo techniques, to uncover the mechanism for cell fate decisions in oligodendrocyte precursor cells, in the healthy and diseased brain. Oligodendrocytes arise from oligodendrocyte precursor cells (OPCs) and accomplish myelination in the central nervous system to regulate axonal function. Although OPCs are the most abundant proliferative population in the adult and ageing brain, little is known about the underlying molecular regulation of OPC functions. In our lab, we are examining whether OPCs in the adult central nervous system decide about their fate by undergoing asymmetric divisions, whether the underlying mechanism of asymmetric cell divisions in mammalian cells diverge from the process found in Drosophila neuroblasts, whether this divergence involves epigenetic regulators and is there a cell intrinsic or extrinsic mechanism that determines whether OPC divisions are symmetrical or asymmetrical.

http://petritschlab.ucsf.edu

_______________________________________________________________________

SU

ND

AY

|

AP

RIL

15

, 2

018


Genome-wide association study of acute lymphoblastic leukemia in children with Down syndrome

Authors*: Austin L. Brown, Adam J. de Smith, Michael E. Scheurer, Noah A. Kallsen, Shanna A. Peyton, Gareth E. Davies, Erik A. Ehli, Michael E. Zwick, Naomi Winick, Kelly Maloney, Anne L. Angiolillo, Reuven Schore, MIchael M. Burke, Wanda L. Salzer, Nyla A.Heerema, Andrew J. Carroll, III, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Elizabeth A. Raetz, Elanor Feingold, Stephanie L. Sherman, Wenjian Yang, Meenakshi Devidas, Kyle Walsh, Andrew T. DeWan, Maria S. Pombo-de-Oliveira, Jeffrey W. Taub, Daniel Sinnett, Jasmine Healy, Jillian M. Birch, Lisa F. Barcellos, Helen Hansen Ivan Smirnov, Charles G. Mullighan, Stephen P. Hunger, Ching-Hon Pui, Mignon Loh, Joe L. Wiemels, Xiaomei Ma, Catherine Metayer, Beth A. Mueller, Mary V. Relling, Jun J. Yang, Philip J. Lupo, Karen R. Rabin


Wiemels Research Interests: The causes of most human cancers are unclear, but appear to be related to miscues in normal tissue developmental pathways, mutations (genetic and epigenetic) in critical genes caused by errors, infection, and chemicals, and a failure of recognition and removal of tumors by the immune system. Dr. Wiemels studies these factors as potential causes of hematopoietic and brain tumors. Large population-based studies of human cancer in the San Francisco Bay Area and State of California form a basis for examining the origin of these cancers, with a focus on future prevention. This type of research is highly collaborative, and Dr. Wiemels works with several epidemiologists, geneticists, clinicians, biologists, and statisticians.

http://profiles.ucsf.edu/joe.wiemels

_______________________________________________________________________

A meta-analysis of genome-wide association studies of multiple myeloma among African Americans

Authors*: Zhaohui Du, Chi Song, Kristin Rand, Niels Weinhold, David Van Den Berg, Amie Hwang, Xin Sheng, Victor Hom, Sikander Ailawadhi, Ajay K. Nooka, Seema Singhal, Karen Pawlish, Edward S. Peters, Cathryn Bock, Ann Mohrbacher, Alexander Stram, Sonja I. Berndt, William Blot, John David Carpten, Antoinette Stroup, Andrew Olshan, Wei Zhang, African Ancestry Breast & Prostate Consortium, Stephen Chanock, Jayesh Mehta, Graham A. Colditz, Jeffrey Wolf, Thomas G. Martin, Michael Tomasson, Mark A. Fiala, Howard Terebelo, Nalini Janakiraman, Laurence Kolonel, Loic LeMarchand, Elad Ziv, Daniel Stram, Ravi Vij, Leon Bernal-Mizrachi, Gareth J. Morgan, Jeffrey A. Zonder, Carol Ann Huff, Sagar Lonial, Robert Z. Orlowski, David V. Conti, Christopher A. Haiman, Wendy Cozen


Ziv Research Interests: Dr. Ziv’s group focuses on identifying genetic variations that underlie risk for malignancies by using insights from epidemiology and population genetics. A major interest has been genetic susceptibility to breast cancer among Latinas. Using a combination of admixture mapping and genome wide association, they have identified genetic variants that are unique among Latinas and are associated with strong protection against breast cancer susceptibility. They are currently using a whole exome sequencing approach to identify breast cancer risk variants among Latinas. Dr. Ziv’s group has successfully mapped the genes for ethnic neutropenia in African Americans. They are also currently studying the genetic variation underlying multiple myeloma susceptibility and progression.

http://cancer.ucsf.edu/people/profiles/ziv_elad.3779

_______________________________________________________________________

SU

ND

AY

|

AP

RIL

15

, 2

018


Evaluating glioma risk associated with extent of European admixture in African-Americans and Latinos

Authors*: Quinn T. Ostrom, Kathleen M. Egan, L. Burt Nabors, Travis Gerke, Reid C. Thompson, Jeffrey J. Olson, Renato LaRocca, Sajeel Chowdhary, Jeanette E. Eckel-Passow, Georgina Armstrong, John K. Wiencke, Christopher I. Amos, Jonine L. Bernstein, Elizabeth B. Claus, Dora Il’yasova, Christoffer Johansen, Daniel H. Lachance, Rose Lai, Ryan T. Merrell, Sara H. Olson, Siegal Sadetzki, Joellen Schildkraut, Sanjay Shete, Richard S. Houlston, Robert B. Jenkins, Beatrice Melin, Melissa L. Bondy, Jill S. Barnholtz-Sloan


_______________________________________________________________________

Probing the non-enhancing component of glioblastoma: Targeting what is left behind

Authors*: Sen Peng, Rebecca Halperin, Harshil Dhruv, Sara Byron, Christophe Legendre, Joanna Phillips, Michael Prados, Michael Berens, Nhan Tran


Prados Research Interests: Dr. Prados is a an internationally known Neuro-oncology expert. He led the Adult Brain Tumor Consortium for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a multi-institutional consortium of now 15 major academic centers across the United States. Currently Dr. Prados is Professor Emeritus at UCSF devoting his efforts towards pediatric Neuro-Oncology clinical and translational research. He is the co-Project Leader of a pediatric brain tumor SPORE project at UCSF and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research and the translational studies that precede and inform those trials in both adults and children. He is part of the Editorial board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and a member of the NCI/CTEP Brain Malignancies Steering Committee. In 2014 he was awarded the Victor Levin Award for lifetime clinical research excellence from the Society of Neuro-Oncology.

http://cancer.ucsf.edu/people/profiles/prados_michael.3603

_______________________________________________________________________

SU

ND

AY

|

AP

RIL

15

, 2

018


B-lymphoid transcriptional repression of the pentose phosphate pathway reveals a unique therapeutic vulnerability of B cell malignancies

Authors*: Gang Xiao, Zhengshan Chen, Lai N. Chan, Daniel Braas, Thomas G. Graeber, Huimin Geng, Hassan Jumaa, Xiaoyan Jiang, Markus Müschen


Geng Research Interests: Dr. Geng’s research is focused on functional genomics and epigenomics of lymphoma and leukemia using computational approaches on genome-wide array and deep sequencing data, including RNA-seq, Whole Exome-Seq, ChIP-seq, miRNA-seq and DNA methylation eRRBS-seq. Applying bioinformatic methods coupled with in vitro and in vivo experiments, they are interested in identifying and evaluating new prognostic and disease-classification biomarkers and novel therapeutic targets for different forms of lymphoma and leukemia.

http://profiles.ucsf.edu/huimin.geng

_______________________________________________________________________

Genome-wide and focused CRISPR screens to study PARP inhibitor resistance mediated by mutations in PARP1

Authors*:Stephen J. Pettitt, Dragomir B. Krastev, Inger Brandsma, Amy Dréan, Feifei Song, Maria I. Harrell, Rachel Brough, Jessica Frankum, Jung-Min Lee, Elizabeth M. Swisher, Kosuke Yusa, Alan Ashworth, Christopher J. Lord

Abstract #: 410Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/7002Presentation Date/Time: April 15, 2018, 1:00 PM - 5:00 PMLocation: Section 18Presentation: Poster Session

_______________________________________________________________________

SU

ND

AY

|

AP

RIL

15

, 2

018


High expression of miR-182 promotes prostate cancer aggressiveness in African-Americans compared to Caucasians

Authors*: Marisa Shiina, Yutaka Hashimoto, Guoren Deng, Varahram Shahryari, Majid Shahana, Soichiro Yamamura, Priyanka Kulkarni, Pritha Dasgupta, Divya Bhagirath, Sharanjot Sharan, Yuichiro Tanaka, Rajvir Dahiya


Dahiya Research Interests: My group, which is part of the Urology Research Center at the VAMC/UCSF under the leadership of Dr. Peter Caroll, focuses on mechanisms of growth control in GU disorders, especially prostate and renal cancer. We have developed various novel methods for evaluating epigenetic pathways, microRNAs, gene regulation, and function in these diseases both in in vitro and in vivo models. In particular we are studying the role of microRNAs in the progression and metastasis of prostate cancer, diet, miRNAs, epigenetic changes in prostate cancer and wnt antagonist genes in kidney tumor progression and metastasis.

https://urology.ucsf.edu/people/rajvir-dahiya

_______________________________________________________________________

Up-regulation of miR-130b is involved in prostate cancer racial disparity thorough FHIT- β-catenin pathway inactivation

Authors*: Yutaka Hashimoto, Masrisa Shiina, Taku Kato, Soichiro Yamamura, Yuichiro Tanaka, Shahana Majid, Sharanjot Saini, Varahram Shahryari, Priyanka Kulkarni, Pritha Dasgupta, Divya Bhagiratha, Nadeem Bhat, Guoren Deng, Laura Tabatabai, Deepak Kumar, Rajvir Dahiya




_______________________________________________________________________

SU

ND

AY

|

AP

RIL

15

, 2

018


Role of a novel microRNA gene at frequently deleted chromosome 8p region in prostate cancer

Authors*: Divya Bhagirath, Thao Yang, Shahana Majid, Varahram Shahryari, Soichiro Yamamura, Z. Laura Tabatabai, Rajvir Dahiya, Guoren Deng, Sharanjot Saini


Saini Research Interests: A major clinical challenge in prostate cancer is the elucidation of pathways of tumor progression, recurrence and metastasis, which could lead to the design of better diagnostic and therapeutic strategies against the disease. Towards this, our current research is primarily focused on delineating the molecular mechanisms driving prostate cancer progression, recurrence and metastasis. We are particularly interested in understanding key microRNA-mediated molecular pathways in prostate cancer with a long term objective of development of microRNAs as alternative biomarkers for the disease. We have identified important microRNA regulators of prostate cancer metastasis and also elucidated the regulatory role of key microRNAs in prostate cancer stem cells.

http://cancer.ucsf.edu/people/profiles/saini_sharanjot.8680

_______________________________________________________________________

IL-11, a novel diagnostic biomarker for lung adenocarcinoma, is involved in lung cancer tumorigenesis

Authors*: Laura Ojeda Márquez, Patricia Yagüe Sanz, Sonia Molina Pinelo, Amancio Carnero Moya, Alejandro Sweet-Cordero, Luis Paz-Ares Rodríguez, Irene Ferrer Sánchez


Sweet-Cordero Research Interests: My lab works to identify novel therapeutic approaches for cancer that target the genetic mutations & altered signaling networks specific to cancer cells. We use functional genomics applied to mouse & human systems to understand transcriptional networks regulating the outcome of specific oncogenic mutations & to understand how cancers become treatment resistant. We have 2 primary disease interests: lung cancer & pediatric sarcomas. Our lung cancer work focuses on elucidating the tissue-specific oncogenic effects of KRAS in lung cancer. We have identified synthetic vulnerabilities in the Ras pathway & are particularly interested in understanding how other genetic mutations cooperate with Ras. We also study intra-tumor heterogeneity & the possible role of stem-like cells in lung pathogenesis. Our lab has identified a novel potential therapy for lung cancer based on blocking fibroblast-epithelial cell signaling. Our pediatric cancer work is focused on using genomic approaches to identify novel oncogenic drivers in osteosarcoma & Ewing sarcoma. We have established patient-derived xenograft models for these & other pediatric solid tumors.

http://cancer.ucsf.edu/people/profiles/sweetcordero_alejandro.8106

_______________________________________________________________________

SU

ND

AY

|

AP

RIL

15

, 2

018


Pathway-directed high-throughput drug screen identifies PI3K inhibitors that synergistically potentiate antitumor activity of HDAC inhibitors in cutaneous T-cell lymphoma

Authors*: Chi-Heng Wu, Chen-Yen Yan , Taha Rakhshandhroo, Laura Pincus, Sourav Bandyopadhyay, Frank McCormick, Weiyun Ai


_______________________________________________________________________

Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG

Authors*: Anne Steino, Beibei Zhai, Jeffrey A. Bacha, Dennis M. Brown, Mads Daugaard, Sabine Mueller


Mueller Research Interests: The laboratory of Dr. Sabine Mueller focuses on translational research in pediatric neuro-oncology. A key focus is the development and characterization of patient derived xenograft (PDX) models for diffuse intrinsic pontine gliomas (DIPG) and other pediatric high grade gliomas (pHGGs). In particular, the Mueller lab investigates the genomic heterogeneity of DIPGs and other pHGGs. Additionally, they are exploring the utility of liquid biopsies by assessing circulating tumor DNA and correlating this with disease response. Further, the laboratory is exploring central nervous system (CNS) directed delivery strategies, such as convection enhanced delivery (CED) in combination with nanotechnology, in these PDX models. The laboratory has several industry partnerships to test new agents as single agents and in combination therapy strategies with other agents as well as radiation therapy.

http://cancer.ucsf.edu/people/profiles/mueller_sabine.4800

_______________________________________________________________________

SU

ND

AY

|

AP

RIL

15

, 2

018


COP1 E3 ligase regulates response to oncogenic MAPK pathway inhibition

Authors*: Manasi K. Mayeka, Luping Lin, Trever G. Bivona


Bivona Research Interests: Our team uses the tools of precision medicine to improve the molecular diagnosis and targeted therapy of patients with solid cancers, including lung cancer. Our program focuses on identifying and functionally characterizing the molecular drivers of tumor growth in individual patients. We study patient samples and clinical data to identify novel potential drivers of tumor initiation, progression, and therapy resistance. We functionally annotate the putative molecular drivers using an integrated approach of genetic and pharmacologic tools. This precision approach to understanding the molecular pathogenesis of lung cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide rationale for novel clinical trials we are launching to improve patient survival.

http://www.bivonalab.net/

_______________________________________________________________________

Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma

Authors*: Peter O’Donnell, Christophe Massard, Bhumsuk Keam, Sang-We Kim, Terry Friedlander, Myung-Ju Ahn, Michael Ong, Michael Gordon, Marcus Butler, Scott Antonia, Gerardo Colon-Otero, Martin Gutierrez, Sumati Gupta, Alexander Spira, Alexandra Drakaki, Michele Maio, Feng Xiao, Natasha Angra, Shaad Abdullah, Thomas Powles

Abstract #: CT031Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/11182Presentation Date/Time: April 15, 2018, 1:00 PM - 5:00 PMLocation: Section 42Presentation: Poster Session

Friedlander Research Interests: I am a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. My research is focused on understanding the basic biology of these malignancies and in developing novel therapeutic ways to treat disease. I have a research focus in developing novel immunotherapeutic approaches, particularly in bladder cancer, as well as in developing novel biomarkers, such as circulating tumor cells, to help understand how to better select patients for therapy. As a clinical academic oncologist, I serve as principal investigator or co-investigator on a number of clinical trials in advanced prostate and bladder cancer, which allows us to recruit patients for much of our biomarker work.

http://cancer.ucsf.edu/people/profiles/friedlander_terence.4963

_______________________________________________________________________

SU

ND

AY

|

AP

RIL

15

, 2

018


Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive, basal-like breast cancer

Authors*: Allison P. Drain, Ken Takai, Devon A. Lawson, Laurie E. Littlepage, Marcela Karpuj, Kai Kessenbrock, Annie Le, Kenichi Inoue, Valerie M. Weaver, Zena Werb

Abstract #: LB-055Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/10725Presentation Date/Time: April 15, 2018, 1:00 PM - 5:00 PMLocation: Section 45Presentation: Poster Session

Werb Research Interests: The Werb Lab focuses on breast cancer and the environment, concentrating on puberty as the window of susceptibility for the past 12 years. They concentrate on the molecular mechanisms involved in extracellular matrix remodeling and inflammatory cell function in mammary development and breast cancer metastasis. They have developed and used a variety of new technologies and models ranging from molecular biology to genetically engineered mouse models and patient-derived xenografts to intravital microscopy and 3D culture models. Their major interest is in driving the field of the extracellular microenvironment in development, inflammation, fibrosis, and tumor biology forward technically and conceptually, as well as determining insights from mammary development that help explain breast stem cells, and susceptibility to cancer development and metastasis. Recent studies have shown that ablation of the discoidin domain receptor 1 (DDR1) promotes tissue fibrosis and hypoxia to induce aggressive, basal-like breast cancer.

http://werblab.ucsf.edu

_______________________________________________________________________

Intralesional injection of anti-PD-1 (pembrolizumab) results in increased T cell infiltrate in high risk DCIS

Authors*: Michael J. Campbell, Emma McCune, Jennifer Bolen, Scott VandenBerg, Jo Chien, Jasmine Wong, Laura Esserman

Abstract #: 961Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/7336Presentation Date/Time: April 15, 2018, 4:05 PM - 4:20 PMLocation: Room S406 (Vista Ballroom) - McCormick Place South (Level 4)Presentation: Minisymposium

Esserman Research Interests: Dr. Esserman, surgeon & breast cancer oncology specialist, is the Carol Franc Buck Breast Care Center Director and co-leads the Breast Oncology Program. Her research is on improving healthcare value through integrating translational science, clinical informatics, systems re-engineering & clinical care delivery. In 2005, she received the NCI SPORE Investigator of the Year Award. In 2016 she received the Arbuckle Award from Stanford Graduate School of Business for Excellence in Management & was named to TIME’s 100 most influential people list. She is PI of the I-SPY TRIAL program, now a model for translational research & innovation in clinical trial design. She launched the Athena Breast Health Network to follow women from screening through treatment & outcomes, incorporating the latest in molecular testing & web-based tools. Athena just launched the WISDOM study to compare personalized vs annual breast cancer screening in 100,000 women and to predict who gets what kind of cancer.

http://profiles.ucsf.edu/laura.esserman

_______________________________________________________________________

SU

ND

AY

|

AP

RIL

15

, 2

018


Systematic identification of the actionable kinase dependencies of chemotherapy-resistant triple-negative breast cancer

Authors*: Jean-Philippe F. Coppe, Pan Bo, Carolien van der Borden, Nina Koemans, Changjun Wang, Denise Wolf, Christina Yau, Sietske Bakker, Marij Hartog, Miki Mori, Ana Ruiz-Saenz, Zhongzhong Chen, Aleksandra Olow, Pei Rong Evelyn Lee, Laura van ’t Veer

Abstract #: 956Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/2981Presentation Date/Time: April 15, 2018, 4:35 PM - 4:50 PMLocation: Room S102 - McCormick Place South (Level 1)Presentation: Minisymposium

van’t Veer Research Interests: Dr. van ’t Veer’s research focuses on personalized medicine & advancing patient management based on knowledge of the genetic makeup of the tumor as well as the genetic makeup of the patient. Her laboratory investigates human kinases & how kinase inhibitors elicit response & resistance, which is also utilized to understand agent efficacy in the I-SPY 2 TRIAL. She is the PI of the Athena Breast Health Network, a 150,000 women cohort study evaluating new paradigms to enhance breast health. She leads the targeted genome testing of 100,000 women for 9 breast cancer susceptibility genes and a selection of ~100 known susceptibility SNPs. She is one of the PIs for the NIH Big Data to Knowledge Center Translational Genomics, facilitating worldwide standardization of sharing annotated genomics data.

http://cancer.ucsf.edu/people/profiles/vantveer_laura.3358

_______________________________________________________________________

TME Chair: Opening remarks

Authors*: Valerie M. Weaver

Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/911Presentation Date/Time: April 15, 2018, 6:00 PM - 6:15 PMLocation: Room S106 - McCormick Place South (Level 1)Presentation: Town Meeting

Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins, syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate. More recently, we have broadened our program to include an exploration into the interplay between tissue fibrosis, tissue tension and immune regulation.

http://weaverlab.ucsf.edu

_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


MONDAY | APRIL 16, 2018

Epithelial-to-mesenchymal transition conveys resistance to restrictive growth conditions through increased autophagic flux

Authors*: Lei Zhao, Jones Nauseef, Marisa Buchakjian, Matthew Barnes, Michael Henry

Abstract #: 1093Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/4495Presentation Date/Time: April 16, 2018, 8:00 AM - 12:00 PMLocation: Section 4Presentation: Poster Session



_______________________________________________________________________

Role of a prometastatic miRNA as a negative regulator of the key metastasis suppressor genes in renal cell carcinoma

Authors*: Nadeem S. Bhat, Altaf A. Dar, Sharanjot Saini, Varahram Shahryari, Soichiro Yamamura, Yuichiro Tanaka, Taku Kato, Yutaka Hashimoto, Marisa Shiina, Priyanka Kulkarni, Pritha Dasgupta, Z Laura Tabatabai, Guoren Deng, Rajvir Dahiya, Shahana Majid


Majid Research Interests: The Majid lab, located Urology Research Center at the VAMC/UCSF, focuses in the area of urological cancers to understand the etiology and to develop novel molecular biomarkers for initiation, progression and metastasis with special emphasis on prostate cancer. We have been working in the field of microRNAs, genetics and epigenetics of urologic cancers. Cancer progression markers are identified by employing genome-wide approaches, and utilizing cells culture and mouse models as well as tissues from patients. The objective of the lab is to identify novel therapeutic targets or valuable biomarkers to establish rational therapeutic strategies for the diagnosis and treatment of cancer.

http://profiles.ucsf.edu/shahana.majid

_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


Exploring the roles of Suppressor of Fused in the postnatal neurogenic niche and tumorigenesis

Authors*: Jesse Garcia Castillo, Hector G. Gomez, David Aguilar, Samuel J. Pleasure, Odessa Yabut


_______________________________________________________________________

Rare variants in DNA damage repair genes are associated with male breast cancer predisposition

Authors*: Sarah L. Maguire, Katarzyna Tomczyk, Eleni Perrakis, Edward Saunders, Daniel Leongamornlert, ZSofia Kote-Jarai, Rosalind Eeles, Montserrat Garcia-Closas, Paul Pharoah, Douglas Easton, Christopher J. Lord, Alan Ashworth, Anthony Swerdlow, Nick Orr


_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


Differences of cytochrome P450 1B1 polymorphisms on prostate cancer risk between races

Authors*: Taku Kato, Yutaka Hashimoto, Ryan Wong, Yozo Mitsui, Shigekatsu Maekawa, Soichiro Yamamura, Shahana Majid, Sharanjot Saini, Varahram Shahryari, Laura Tabatabai, Hiroaki Shiina, Rajvir Dahiya, Takashi Deguchi, Yuichiro Tanaka


Tanaka Research Interests: Dr. Tanaka’s research at the UC/VA Urology Research Center San Francisco over the years has involved a variety of areas that include methylation, polymorphism, non-coding RNA, aging, gene function and signaling pathways. Specifically, his research focuses on finding risk factors for urological cancers by utilizing human specimens, assessing the functional role of these biomarkers at the cellular and molecular levels and use of animal models, and determining its regulation in the cell; as he attempts to understand the mechanisms of the carcinogenesis process. The cancer types that he’s been studying involve prostate, kidney and bladder. By engaging in his research interest, results can lead to biomarkers as well as potential therapeutic implications for urological cancers.

http://profiles.ucsf.edu/yuichiro.tanaka

_______________________________________________________________________

Multi-scale mapping of the physical and functional architecture of the cancer cell

Authors*: Fan Zheng, Michael K. Yu, Minkyu Kim, Keiichiro Ono, Mitchell Flagg, Jason F. Kreisberg, Nevan Krogan, Trey Ideker


Krogan Research Interests: Research in the Krogan lab focuses on high-throughput network biology to derive mechanistic insights into cellular processes and disease conditions, with a particular emphasis on cancer, pathogenesis, psychiatric disorders and heart disease. Cancer research and treatment is increasingly dependent on knowledge of biological networks of multiple types, including physical interactions among proteins and synthetic-lethal and epistatic interactions among genes. Dr. Krogan is Co-Director of the Cancer Cell Map Initiative (CCMI), which aims to comprehensively detail these complex interactions among cancer genes and proteins using a combination of physical interaction, genetic interaction, and computational approaches. This work will enable the analysis of cancer molecular networks with a view towards pathway and network-based personalized therapy.

http://kroganlab.ucsf.edu

_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


A PARylation biosensor genetic screen to identify novel PARylation targets

Authors*: Dragomir B. Krastev, Stephen J. Pettitt, James Campbell, Alan Ashworth, Christopher J. Lord


_______________________________________________________________________

Targeting histone acetyltransferases to reprogram high C-MYC expressing cancers

Authors*: Elodie M. Da Costa, Gregory Armaos, Annie Beaudry, Chantal Richer, Maxime Caron, Pascal St-Onge, Jeffrey Johnson, Nevan Krogan, Yuka Sai, Michael Downey, Daniel Sinnett, Serge McGraw, Noël J. M. Raynal


Krogan Research Interests: Research in the Krogan lab focuses on high-throughput network biology to derive mechanistic insights into cellular processes and disease conditions, with a particular emphasis on cancer, pathogenesis, psychiatric disorders and heart disease. Cancer research and treatment is increasingly dependent on knowledge of biological networks of multiple types, including physical interactions among proteins and synthetic-lethal and epistatic interactions among genes. Dr. Krogan is Co-Director of the Cancer Cell Map Initiative (CCMI), which aims to comprehensively detail these complex interactions among cancer genes and proteins using a combination of physical interaction, genetic interaction, and computational approaches. This work will enable the analysis of cancer molecular networks with a view towards pathway and network-based personalized therapy.

http://kroganlab.ucsf.edu

_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


Role of catechol-O-methyltransferase gene in prostate cancer

Authors*: Shigekatsu Maekawa, Taku Kato, Yutaka Hashimoto, Marisa Shiina, Ryan K. Wong, Varahram Shahryari, Soichiro Yamamura, Sahana Majid, Sharanjot Saini, Laura Z. Tabatabai, Yukio Homma, Rajvir Dahiya, Yuichiro Tanaka


Tanaka Research Interests: Dr. Tanaka’s research at the UC/VA Urology Research Center San Francisco over the years has involved a variety of areas that include methylation, polymorphism, non-coding RNA, aging, gene function and signaling pathways. Specifically, his research focuses on finding risk factors for urological cancers by utilizing human specimens, assessing the functional role of these biomarkers at the cellular and molecular levels and use of animal models, and determining its regulation in the cell; as he attempts to understand the mechanisms of the carcinogenesis process. The cancer types that he’s been studying involve prostate, kidney and bladder. By engaging in his research interest, results can lead to biomarkers as well as potential therapeutic implications for urological cancers.

http://profiles.ucsf.edu/yuichiro.tanaka

_______________________________________________________________________

Autophagic degradation of the endoplasmic reticulum leads to reduced phospholipid biosynthesis in mutant isocitrate dehydrogenase 1 gliomas

Authors*: Pavithra Viswanath, Russell O. Pieper, Joanna J. Phillips, Sabrina M. Ronen


Ronen Research Interests: The goal of the research performed in the Ronen lab is to develop and mechanistically validate robust noninvasive translatable magnetic resonance (MR)–based biomarkers that can be used to identify oncogenic events associated with cancer, and to monitor response to a broad range of therapies including chemotherapy, targeted therapies, immunotherapies etc. To this end, our research uses multinuclearMR spectroscopy (MRS), imaging (MRI) and spectroscopic imaging (MRSI) to probe preclinical cell and animal models of cancer. Putative biomarkers are mechanistically validated using established biochemical, cell and molecular biological methods.

http://cancer.ucsf.edu/people/profiles/ronen_sabrina.3638

_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


The oncogene MYC induces chromosomal instability through dysregulating mitotic progression evoking a dependency on TPX2

Authors*: Julia Rohrberg, Alexandra Corella, Moufida Taileb, Marie-Lena Jokisch, Roman Camarda, Sanjeev Balakrishnan, Alicia Zhou, Andrei Goga


Goga Research Interests: Activation of proto-oncogenes results in alterations of multiple signaling pathways, resulting in the rewiring of cell proliferation, metabolism and small RNA circuits which contribute to the tumorigenic state. Despite the discovery of numerous driver oncogenes in cancer, many of the most prevalent oncogenic alterations, such as activation of MYC or RAS cannot yet be readily blocked with small molecule inhibitors. Our laboratory seeks to elucidate how oncogenes reprogram signaling to uncover new vulnerabilities in cancer cells.

https://www.oncogenes.net

_______________________________________________________________________

STAG2 as a biomarker for prediction of recurrence in papillary non-muscle invasive bladder cancer

Authors*: Alana Lelo, Brent T. Harris, Deborah L. Berry, Krysta Chaldekas, Anagha Kumar, David Solomon, Jeffry Simko, Pritish Bhattacharyya, Ciaran Mannion, Jung-Sik Kim, George Philips, Todd Waldman


Solomon Research Interests: As a diagnostic pathologist and molecular oncologist, the major focus of Dr. Solomon’s research program is deciphering the molecular pathogenesis of human cancer. His laboratory has been identifying the genetic alterations that define the many different human tumor types and then working to characterize the mechanisms by which these alterations cause tumorigenesis, as well as discovering therapeutic mechanisms for inhibiting the activated signaling pathways in these cancer types. Their work includes the discovery of frequent inactivating mutations of the cohesin complex gene STAG2 in glioblastoma, urothelial bladder carcinoma, and Ewing sarcoma, which define molecular subgroups of these cancers with distinct clinical outcomes. A major focus of the Solomon lab is on understanding the function of the cohesin complex during mammalian development and tumorigenesis and developing novel targeted therapies for cancers harboring cohesin gene mutations.

http://solomonlab.ucsf.edu

_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


Patient-derived HER3 mutations transform ER+ and HER2+ breast cancer cells via MAPK pathway activation

Authors*: Rosalin Mishra, Samar Alanazi, Long Yuan, Thomas Solomon, Tarjani M. Thaker, Natalia Jura, Joan T. Garrett


Jura Research Interests: The main interest of our laboratory is to understand molecular principles of signal transduction events. We investigate them at the level of enzymatic function and molecular structure of signaling proteins. Our current focus is on understanding how membrane-associated kinases, such as receptor tyrosine kinases, assemble into functional complexes and interface with the plasma membrane. We also investigate alternative non-catalytic roles of kinase scaffolds and seek to identify small molecule inhibitors that target these poorly understood kinase functions in human diseases.

http://www.cvri.ucsf.edu/~jura/lab/Jura_Lab_Home.html

_______________________________________________________________________

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Authors*: Khyati N. Shah, Roma Bhatt, Julia Rotow, Julia Rohrberg, Victor Olivas, Golzar Golzar Hemmati, Gregor Krings, Henry J. Haringsma, Andrew D. Simmons, Thomas C. Harding, Andrei Goga, Collin Blakely, Trever Bivona, Sourav Bandyopadhyay


_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


A novel small-molecule compound targeting PBX1-DNA interaction impedes cancer cell survival and carboplatin resistance

Authors*: Yao-An Shen, Jin Jung, Yohan Suryo Rahmanto, Licia Selleri, Ie-Ming Shih, Chi-Mu Chuang, Tian-Li Wang


Selleri Research Interests: The Selleri lab studies the genetic and regulatory basis of how elaborately patterned tissues form during embryonic development and evolution. They combine different genetic approaches, using mouse, chick, pig, and primates as model systems, to understand the mechanisms underpinning basic developmental processes related to cranial and appendicular morphogenesis. They discovered that homeodomain-containing transcription factors of the Pbx family, also known as Hox-cofactors, are critical developmental regulators through the transcriptional control of target genes within tissue-specific regulatory networks. Using genetically-engineered and ethylnitrosourea (ENU)-mutagenized mouse lines and recently employing new animal model systems (such as pigs and primates) the ultimate goal of the lab is to identify novel genes and regulatory networks underlying morphogenesis of embryonic structures, morphological variation, evolution, and human congenital disease.

https://bms.ucsf.edu/faculty/licia-selleri-phd-md

_______________________________________________________________________

Targeting the IL-6 signaling pathway overcomes cetuximab resistance in head and neck squamous cell carcinoma

Authors*: Rachel A. O’Keefe, Neil E. Bhola, David S. Lee, Daniel E. Johnson, Jennifer R. Grandis


Grandis Research Interests: Cetuximab is an EGFR monoclonal antibody that is FDA-approved for the treatment of head and neck cancer. Despite ubiquitous over expression of EGFR in head and neck cancers, only a subset of patients respond to this drug and resistance mechanisms are incompletely understood. The Grandis lab has accumulated evidence that secretion of interleukin 6 (IL6), with subsequent oncogenic signaling represents a potential pathway of cetuximab resistance where co-targeting IL6/ILR-receptor may represent a plausible therapeutic strategy.

http://cancer.ucsf.edu/people/profiles/grandis_jennifer.6048

_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


Molecular and clinical activity of CDX-3379, an anti-ErbB3 monoclonal antibody, in head and neck squamous cell carcinoma: A preoperative “window of opportunity” study

Authors*: Umamaheswar Duvvuri, Jonathan George, Seungwon Kim, Diego Alvarado, Veronique Neumeister, Ahmed Chenna, Thomas Hawthorne, Theresa LaVallee, Jennifer R. Grandis, Julie E. Bauma

Abstract #: CT058Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/11195Presentation Date/Time: April 16, 2018, 8:00 AM - 12:00 PMLocation: Section 42Presentation: Poster Session



_______________________________________________________________________

Tissue mechanics modulates risk to malignancy


Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/603Presentation Date/Time: April 16, 2018, 1:00 PM - 1:25 PMLocation: Room S404 - McCormick Place South (Level 4)Presentation: Recent Advances in Prevention and Interception Research



_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


SAMD9/SAMD9L mutations in familial monosomy 7

Authors*: Victoria Bryant, Jasmine Wong, Jason Schwartz, Tamara Lamprecht, Jing Ma, Charles Mullighan, Mignon Loh, Kevin Shannon, Jeffery Klco


Shannon Research Interests: The Shannon Lab uses inherited predispositions to myeloid leukemia as an entry point to discover mutations that cause human developmental disorders and drive malignant growth. Aberrant Ras signaling and chr 7 deletions are long-term areas of focus. They test novel strategies for treating cancers characterized by hyperactive Ras signaling and characterize mechanisms of response and resistance to conventional and targeted anti-cancer drugs. They have generated a novel collection of primary Kras, Nras, and Nf1 mutant murine leukemias, which they use to perform preclinical trials in vivo. Other work in the lab focuses on generating Ras mutant “knock in” alleles for functional and biochemical studies, testing novel strategies for directly targeting oncogenic Ras proteins, investigating rational drug combinations, and using chromosome engineering to model segmental deletions of 7q22.

http://shannonlab.ucsf.edu

_______________________________________________________________________

Whole genome sequence analysis informs precision medicine of pediatric cancers

Authors*: Bogdan Tanasa, Alex Lee, Marcus Breese, Avanthi Shah, Stan Leung, Heng-Yi Liu, Aviv Spillinger, Kimberly Hazard, Arun Rangaswami, Sheri Spunt, Norm Lacayo, Tabitha Cooney, Eric Alejandro Sweet-Cordero




_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


Machine learning to identify prostate cancer mutations for screening cell-free DNA (cfDNA)

Authors*: Clinton L. Cario, Lancelote Leong, Man-Tzu Wang, John Witte



http://wittelab.ucsf.edu

_______________________________________________________________________

Protein homeostasis adaptation to Hsp70 inhibition in cancer

Authors*: Sara Sannino, Christopher J. Guerriero, Amit J. Sabnis, Trever G. Bivona, Jeffrey L. Brodsky




_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


Tumor cell-adipocyte gap junctions activate lipolysis in breast cancer

Authors*: Roman Camarda, Jeremy Williams, Serghei Malkov, Lisa J. Zimmerman, Suzanne Manning, Dvir Aran, Andrew Beardsley, Daniel Van de Mark, Jeffrey van Haren, Yong Chen, Charles Berdan, Sharon Louie, Celine Mahieu, Juliane Winkler, Elizabeth Willey, John D. Gagnon, Kosaku Shinoda, K. Mark Ansel, Zena Werb, Daniel C. Nomura, Shingo Kajimura, Torsten Wittmann, Atul J. Butte, Melinda E. Sanders, Daniel C. Liebler, Gregor Krings, John A. Shepherd, Andrei Goga


Goga Research Interests: Activation of proto-oncogenes results in alterations of multiple signaling pathways, resulting in the rewiring of cell proliferation, metabolism and small RNA circuits which contribute to the tumorigenic state. Despite the discovery of numerous driver oncogenes in cancer, many of the most prevalent oncogenic alterations, such as activation of MYC or RAS cannot yet be readily blocked with small molecule inhibitors. Our laboratory seeks to elucidate how oncogenes reprogram signaling to uncover new vulnerabilities in cancer cells.

https://www.oncogenes.net

_______________________________________________________________________

Epithelial-to-mesenchymal transition and stemness: Key targets of HOTAIR-miR-203 interaction in renal cell carcinoma

Authors*: Pritha Dasgupta, Priyanka Kulkarni, Shahana Majid, Varahram Shahryari, Yutaka Hashimoto, Nadeem S. Bhat, Marisa Shiina, Guoren Deng, Sharanjot Saini, Soichiro Yamamura Yamamura, Yuichiro Tanaka, Rajvir Dahiya




_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


miR-182-5p suppresses progression of renal cancer through cell cycle arrest by targeting lncRNA MALAT-1

Authors*: Priyanka Kulkarni, Pritha Dasgupta, Shahana Majid, Varahram Shahryari, Marisa Shiina, Yutaka Hashimoto, Nadeem Bhat, Guoren Deng, Sharanjot Saini, Soichiro Yamamura, Yuichiro Tanaka, Rajvir Dahiya




_______________________________________________________________________

Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study

Authors*: Matthew R. Smith, Shibu Thomas, Simon Chowdhury, David Olmos, Jinhui Li, Paul N. Mainwaring, Stéphane Oudard, Felix Y. Feng, Michael Gormley, Deborah S. Ricci, Brendan Rooney, Angela Lopez-Gitlitz, Margaret K. Yu, Eric J. Small


Small Research Interests: Dr. Eric Small’s current research program is based in the hypothesis that resistance to hormonal therapy for prostate cancer occurs when cancer cells exploit common cellular processes ultimately to evade the therapies, allowing disease progression. By identifying such “adaptive” mechanisms and inhibiting them, it is expected that treatment resistance may be delayed or prevented, profoundly improving the care of men affected by this fatal disease.

http://cancer.ucsf.edu/people/profiles/small_eric.3671

_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


Evaluation of ANG/TIE/hypoxia pathway genes and signatures as predictors of response to trebananib (AMG 386) in the neoadjuvant I-SPY 2 TRIAL for Stage II-III high-risk breast cancer

Authors*: Denise M. Wolf, Christina Yau, Lamorna Brown-Swigart, Gillian Hirst, I-SPY 2 TRIAL Investigators, Smita Asare, Richard Schwab, Don Berry, Laura Esserman, Kathy S. Albain, Brian Leland-Jones, Laura van ‘t Veer




_______________________________________________________________________

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY 2 breast cancer patients

Authors*: Pei Rong Evelyn Lee, Zelos Zhu, Denise Wolf, Christina Yau, William Audeh, Annuska Glas, Lamorna Brown-Swigart, Gillian Hirst, Angela DeMichele, I-SPY 2 TRIAL Investigators, Laura Esserman, Laura van ‘t Veer




_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


Genome-informed therapy for osteosarcoma

Authors*: Leanne Sayles, Marcus Breeese, Amanda Koehne, Bogdan Tanasa, Stanley Leung, Alex Lee, Avanthi Shah, Krystal Straessler, Kim Hazard, Mi-Ok Kim, Alejandro Sweet-Cordero




_______________________________________________________________________

Status of TGFbeta signaling determines PARP inhibitor sensitivity in head and neck cancer

Authors*: Qi Liu, Lin Ma, Luis Palomero, Miquel Àngel Pujana, Trevor Jones, Patrick Ha, John Murnane,Mary Helen Barcellos-Hoff


_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


The biological effects and therapeutic potential of directly targeting K-Ras

Authors*: Andrew L. Wolfe


_______________________________________________________________________

Identifying synthetic lethal interactions in castration-resistant prostate cancer using HSP40 and HSP70 inhibitors

Authors*: Michael A. Moses, Genesis Rivera-Marquez, Isabelle Taylor, Hao Shao, Jason Gestwicki, Jane Trepel, Len Neckers


Gestwicki Research Interests: We are interested in how molecular chaperones, such as Hsp70 and Hsp90, work together to maintain protein homostasis, which is the balance of protein folding, trafficking and turnover. Understanding this delicate balance is important because protein homeostasis is dramatically disrupted in many diseases, especially neurodegeneration and cancer. Our approach is to create small molecules that disrupt (or promote) interactions between chaperones. Using these chemical probes, we perturb protein-protein interactions and learn how this chaperone network is “wired”. These studies have taken us into many exciting areas of biotechnology and chemical biology.

http://gestwickilab.ucsf.edu

_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


E-cadherin/ROS1 inhibitor synthetic lethality inbreast cancer

Authors*: Ilirjana Bajrami, Rebecca Marlow, Marieke van de Ven, Rachel Brough, Helen N. Pemberton, Jessica Frankum1, Fei Fei Song, Rumana Rafiq, Asha Konde1 Malini Menon, James Campbell, Aditi Gulati, Rahul Kumar, Stephen J. Pettitt, Mark D. Gurden, Marta Llorca Cardenosa, Irene Chong, Patrycja Gazinska, Fredrik Wallberg, Elinor J. Sawyer, Lesley-Ann Martin, Mitch Dowsett, Spiros Linardopoulos, Colm Ryan, Patrick W. Derksen, Jos Jonkers, Andrew N.J. Tutt, Alan Ashworth, Christopher J. Lord


_______________________________________________________________________

Imputation of the prostate cancer transcriptome in over 230,000 men reveals novel germline-somatic interaction mechanism of cancer risk

Authors*: Nima C. Emami, Joshua Hoffman, Elad Ziv, John S. Witte




_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


Defining New Immunotherapeutic Targets through Deep Molecular Characterization - Chairperson

Authors*: Matthew Spitzer

Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/session/562Presentation Date/Time: April 16, 2018, 3:00 PM - 5:00 PMLocation: Room S100 (Grand Ballroom) - McCormick Place South (Level 1)Presentation: Minisymposium

_______________________________________________________________________

Clonal deletion of tumor-specific T cells by combination checkpoint blockade compromises antitumor efficacy in low tumor burden states

Authors*: Chien-Chun Steven Pai, Xiaoqing Lu, Donald Simons, Michel DuPage, Kole T. Roybal, Mingyi Chen, Serena Kwek, Amy-Jo Casbon, Gillian A. Kinsbury, Lawrence Fong

Abstract #: 2981Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/4161Presentation Date/Time: April 16, 2018, 3:35 PM - 3:50 PMLocation: Room S100 (Grand Ballroom) - McCormick Place South (Level 1)Presentation: Minisymposium

Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of solid malignancies. We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy.

http://hemonc.ucsf.edu/fonglab/

_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignancies

Authors*: Jaewoong Lee, Huimin Geng, Zhengshan Chen, Gang Xiao, Kadriye Nehir Cosgun, Francesca Zammarchi, Patrick Van Berkel, Ari Melnick, Elisabeth Paietta, Markus Muschen

Abstract #: 2983Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/4169Presentation Date/Time: April 16, 2018, 4:05 PM - 4:20 PMLocation: Room S100 (Grand Ballroom) - McCormick Place South (Level 1)Presentation: Minisymposium



_______________________________________________________________________

Molecular Predictors of Response, Mediators of Resistance, Mechanisms of Action, Pharmacodynamic Markers, and Novel Disease Subsets - Chairperson

Authors*: Catherine C. Smith

Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/session/549Presentation Date/Time: April 16, 2018, 3:00 PM - 5:00 PMLocation: Room W196 - McCormick Place West (Level 1)Presentation: Minisymposium

Smith Research Interests: My laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML). We have a particular emphasis on AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is mutated in ~30% of AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. We employ a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize samples from patients who have undergone therapy in real time. This strategy allows us to interrogate how tumors can evolve under the selective pressure of cancer therapy and allows us to devise ways to circumvent these evolutionary adaptations.

http://cancer.ucsf.edu/people/profiles/smith_catherine.3369

_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


A tyrosine kinase interactome reveals network states that guide the use of targeted therapies in cancer

Authors*: Swati Kaushik, Gwendolyn Jang, Hsien-Ming Hu, Khyati Shah, Xin Zhao, John Jascur, John Von Dollen, Erik Verschueren, Jeffrey Johnson, Nevan Krogan, Sourav Bandyopadhyay

Abstract #: 3297Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/9530Presentation Date/Time: April 16, 2018, 3:15 PM - 3:20 PMLocation: Room S402 - McCormick Place South (Level 4)Presentation: Poster Discussion Session

_______________________________________________________________________

The molecular landscape of oncogenic signaling pathways in The Cancer Genome Atlas

Authors*: Augustin Luna, Konnor La, Sofia Dimitriadoy, David L. Liu, Havish S. Kantheti, Zachary Heins, Angelica Ochoa, Benjamin Gross, Jianjiong Gao, Hongxin Zhang, Ritika Kundra, Cyriac Kandoth, Istemi Bahceci, Leonard Dervishi, Ugur Dogrusoz, Wanding Zhou, Hui Shen, Peter W. Laird, Alice H. Berger, Trever G. Bivona, Alexander J. Lazar, Gary Hammer, Thomas Giordano, Lawrence Kwong, Grant McArthur, Chenfei Huang, Mitchell J. Frederick, Frank McCormick, Matthew Meyerson, The Cancer Genome Atlas Research Network, Eliezer Van Allen, Andrew D. Cherniack, Giovanni Ciriello, Chris Sander, Nikolaus Schultz

Abstract #: 3302Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/9805Presentation Date/Time: April 16, 2018, 3:40 PM - 3:45 PMLocation: Room S402 - McCormick Place South (Level 4)Presentation: Poster Discussion Session



_______________________________________________________________________

MO

ND

AY

|

AP

RIL

16

, 2

018


Sequential transcriptomic and phosphorylation landscape of acute myelogenous leukemia (AML) on the single-cell level

Authors*: Victoria E. Wang, Graham Heimberg, Gregory K. Behbehani, Chun Ye, Charalambos Babis Andreadis

Abstract #: 2957Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/6346Presentation Date/Time: April 16, 2018, 4:35 PM - 4:50 PMLocation: Room W196 - McCormick Place West (Level 1)Presentation: Minisymposium

Andreadis Research Interests: Dr. Andreadis studies the interplay of cancer genetics and traditional pharmacogenetics (germline) as it pertains to prognosis and treatment response in patients with cancer, and especially hematologic malignancies. His clinical experience combined with his molecular epidemiology statistical expertise have been the primary drivers for this work. He has identified patterns of gene expression in the redox stress defense pathway as significant determinants of clinical outcomes in patients with Diffuse Large B-cell Lymphoma. He is currently the PI of an international NIH-funded collaboration to study the genetic determinants of response to and toxicity of autologous transplantation among patients with AML, as part of the PGRN-CGM Global Alliance for Pharmacogenomics. This work has identified several significant host germline variants that are associated with leukemia-free survival and interact with known clinical and genetic risk factors.

http://cancer.ucsf.edu/people/profiles/andreadis_babis.3784

_______________________________________________________________________

Radiation Science and Medicine Working Group Town Hall Meeting and Networking Reception - Chairperson Elect

Authors*: Mary Helen Barcellos-Hoff

Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/session/918Presentation Date/Time: April 16, 2018, 5:00 PM - 7:00 PM Location: Great Lakes E-G - Marriott Marquis Chicago HotelPresentation:

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Joint Cancer Immunology (CIMM) / Tumor Microenvironment (TME) Working Groups Evening Scientific Session - Closing Remarks


Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/session/5Presentation Date/Time: April 16, 2018, 7:45 PM - 8:00 PMLocation: Room S103 - McCormick Place South (Level 1)Presentation: Special Session



_______________________________________________________________________

TUESDAY | APRIL 17,2018

A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer

Authors*: Patrick A. Ott, Ramaswamy Govindan, Aung Naing, Terence W. Friedlander, Kim Margolin, Jessica J. Lin, Nina Bhardwaj, Matthew D. Hellmann, Lakshmi Srinivasan, Joel Greshock, Melissa Moles, Richard B. Gaynor, Matthew J. Goldstein, Siwen Hu-Lieskovan

Abstract #: CT125Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/11247Presentation Date/Time: April 17, 2018, 8:00 AM - 12:00 PMLocation: Section 42Presentation: Poster Session

Friedlander Research Interests: I am a clinical and translational oncologist specializing in cancers of the genitourinary tract, specifically bladder and prostate cancers. My research is focused on understanding the basic biology of these malignancies and in developing novel therapeutic ways to treat disease. I have a research focus in developing novel immunotherapeutic approaches, particularly in bladder cancer, as well as in developing novel biomarkers, such as circulating tumor cells, to help understand how to better select patients for therapy. As a clinical academic oncologist, I serve as principal investigator or co-investigator on a number of clinical trials in advanced prostate and bladder cancer, which allows us to recruit patients for much of our biomarker work.

http://cancer.ucsf.edu/people/profiles/friedlander_terence.4963

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Establishment of an oral tongue squamous cell carcinoma cell line from a never-smoking patient

Authors*: Steven J. Wang, Saurabh Asthana, Annemieke van Zante, Adam B. Olshen, Frank McCormick, Osamu Tetsu

Abstract #: 3104 Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/6058Presentation Date/Time: April 17, 2018, 8:00 AM - 12:00 PMLocation: Section 4Presentation: Poster Session

Tetsu Research Interests: The Tetsu Laboratory is interested in the mechanisms underlying initiation and progression of various malignancies originated from endoderm; lung, colon and pancreatic cancers. They have exploited the cell signaling pathways that make the cancers different from normal tissues. More recently, their research interests have focus on drug resistance to EGFR and Ras inhibitors. In order to establish truly effective treatments, they have proposed a multi-drug combination therapy targeting the origin of acquired resistant cells, as reduction of this subset may prevent emergent resistance to the kinase inhibitors. In this era of precision medicine, they intend to design the most relevant combination to overcome the patient-specific drug resistance.

http://cancer.ucsf.edu/people/profiles/tetsu_osamu.3684

_______________________________________________________________________

Children with acute lymphoblastic leukemia have increased arginase 2 at birth, implicating immunosuppression in leukemogenesis

Authors*: Amalie B. Nielsen, Mi Zhou, Adam de Smith, Lucie McCoy, Helen Hansen, Paige Bracci, Libby Morimoto, Scott Kogan, Catherine Metayer, Xiaomei Ma, Joseph Wiemels


Wiemels Research Interests: The causes of most human cancers are unclear, but appear to be related to miscues in normal tissue developmental pathways, mutations (genetic and epigenetic) in critical genes caused by errors, infection, and chemicals, and a failure of recognition and removal of tumors by the immune system. Dr. Wiemels studies these factors as potential causes of hematopoietic and brain tumors. Large population-based studies of human cancer in the San Francisco Bay Area and State of California form a basis for examining the origin of these cancers, with a focus on future prevention. This type of research is highly collaborative, and Dr. Wiemels works with several epidemiologists, geneticists, clinicians, biologists, and statisticians.

http://profiles.ucsf.edu/joe.wiemels

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Utilizing digital pathology to understand breast epithelial characteristics of benign breast disease among women undergoing diagnostic image-guided breast biopsy

Authors*: Maeve Mullooly, Samantha Puvanesarajah, Shaoqi Fan, Ruth M. Pfeiffer, Linnea Olsson, Manila Hada, Erin L. Kirk, Pamela M. Vacek, Donald L. Weaver, John A. Shepherd, Amir P. Mahmoudzadeh, Jeff Wang, Stephen M. Hewitt, Sally D. Herschorn, Mark E. Sherman, Melissa A. Troester, Gretchen L. Gierach


_______________________________________________________________________

Associations of plasma trimethylamine N-oxide (TMAO), choline, and betaine with the gut microbiome and biomarkers of inflammation and cardiometabolic risk in the Multiethnic Cohort

Authors*: Benjamin C. Fu, Meredith AJ Hullar, Timothy W. Randolph, Adrian A. Franke, Kristine R. Monroe, Iona Cheng, Lynne R. Wilkens, John Shepherd, Loïc Le Marchand, Unhee Lim, Johanna W. Lampe

Abstract #: 3268 Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/2517Presentation Date/Time: April 17, 2018, 8:00 AM - 12:00 PMLocation:Section 11Presentation: Poster Session

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


IMAAGEN study biomarker analysis in patients with long term response to abiraterone acetate with prednisone for non-metastatic castrate resistant prostate cancer

Authors*: Olesya Chornoguz, Dong Shen, Gurpreet Kapoor, Weimin Li, Jennifer Phillips, Charles J. Ryan, E. David Crawford, Neal D. Shore, Willie Underwood, III, Mary-Ellen Taplin8, Philip W. Kantoff, Tracy McGowan

Abstract #: LB-212 Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/10478Presentation Date/Time: April 17, 2018, 8:00 AM - 12:00 PMLocation:Section 43Presentation: Poster Session

Ryan Research Interests: Dr. Ryan’s clinical practice focuses predominantly on advanced prostate cancer as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract. His clinical and research work centers on the design and conduct of clinical trials of novel therapies for advanced prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, androgen receptor targeted therapy and chemotherapy. In addition to clinical trials Dr. Ryan collaborates with many laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate cancer patients.

http://cancer.ucsf.edu/people/profiles/ryan_charles.3649

_______________________________________________________________________

Maternal embryonic leucine zipper kinase (MELK) confers radioresistance in triple-negative breast cancers (TNBC) through a nonhomologous end joining (NHEJ)-mediated pathway

Authors*: Shyam Nyati, Ben Chandler, Eric Olsen, Leah Moubadder, Meilan Liu, Meleah Cameron, Kari Wilder-Romans, Theodore S. Lawrence, Powel H. Brown, Fellix Y. Feng, Lori J. Pierce, Corey Speers


Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers.

https://radonc.ucsf.edu/felix-feng

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Overweight and obese women with high volumetric breast density at high breast cancer risk

Authors*: Natalie J. Engmann, Christopher G. Scott, Matthew R. Jensen, Stacey J. Winham, Lin Ma, Kathleen R. Brandt, Amir Mahmoudzadeh, Serghei Malkov, Dana Whaley, Carrie Hruska, Fang Fang Wu, Diana L. Miglioretti, Aaron D. Norman, John Heine, John Shepherd, Vernon S. Pankratz, Celine M. Vachon, Karla Kerlikowske


Kerlikowske Research Interests: My lab focuses on breast imaging and the epidemiology of invasive breast cancer, DCIS and breast density, and risk prediction models for invasive breast cancer. We have developed cohorts of women at risk for invasive breast cancer and DCIS and developed comprehensive databases that include breast imaging, pathologic, clinical, biomarker, and risk factor data, as well as follow-up for subsequent disease and death.

http://cancer.ucsf.edu/people/profiles/kerlikowske_karla.3457

_______________________________________________________________________

An integrated TCGA pan-cancer clinical data resource to drive high quality survival outcome analytics

Authors*: Jianfang Liu, Tara Lichtenberg, Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich, Christopher C. Benz, Douglas A. Levine, Adrian V. Lee, Larsson Omberg, Denise M. Wolf, Craig D. Shriver, Vesteinn Thorsson


_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


A tyrosine kinase interactome reveals network states that guide the use of targeted therapies in cancer

Authors*: Swati Kaushik, Gwendolyn Jang, Hsien-Ming Hu, Khyati Shah, Xin Zhao, John Jascur, John Von Dollen, Erik Verschueren, Jeffrey Johnson, Nevan Krogan, Sourav Bandyopadhyay


_______________________________________________________________________

The molecular landscape of oncogenic signaling pathways in The Cancer Genome Atlas

Authors*: Francisco Sanchez-Vega, Marco Mina, Joshua Armenia, Walid K. Chatila, Augustin Luna, Konnor La, Sofia Dimitriadoy, David L. Liu, Havish S. Kantheti, Zachary Heins, Angelica Ochoa, Benjamin Gross, Jianjiong Gao, Hongxin Zhang, Ritika Kundra, Cyriac Kandoth, Istemi Bahceci, Leonard Dervishi, Ugur Dogrusoz, Wanding Zhou, Hui Shen8, Peter W. Laird, Alice H. Berger, Trever G. Bivona, Alexander J. Lazar, Gary Hammer, Thomas Giordano, Lawrence Kwong, Grant McArthur, Chenfei Huang, Mitchell J. Frederick, Frank McCormick, Matthew Meyerson, The Cancer Genome Atlas Research Network, Eliezer Van Allen5, Andrew D. Cherniack, Giovanni Ciriello, Chris Sander, Nikolaus Schultz




_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Analysis of telomere length and dysfunction in normal breast tissue from BRCA2 mutation carriers

Authors*: Birna Thorvaldsdottir, Beth A. Cimini, Morgan E. Diolaiti, Katrin Olafsdottir, Jon G. Jonasson, Jorunn E. Eyfjörd


_______________________________________________________________________

Assessing the genetic heterogeneity of localized, multifocal prostate cancer via cell-free DNA

Authors*: Emmalyn Chen, Clinton L. Cario, Lancelote Leong, Karen Lopez, Jeffry P. Simko, Peter R. Carroll, Caroline Tai, John S. Witte




_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Measuring oncogene signaling with transferrin-based PET: From bench to bedside

Authors*: Michael J. Evans, Charles Truillet, Davide Ruggero, Jason S. Lewis, Rahul Aggarwal, Spencer C. Behr


_______________________________________________________________________

Targeting the CLCF1-CNTFR signaling axis using directed evolution for lung cancer therapy

Authors*: Cesar Marquez, Jun Kim, Amato Giaccia, Jennifer Cochran, Alejandro Sweet-Cordero




_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF

Authors*: Trever G. Bivona, Robert Nichols, Franziska Haderk, Carlos Stahlhut,Christopher Schulze, Golzar Hemmati, David Wildes




_______________________________________________________________________

Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race-ethnicity

Authors*: Yalei Chen, Jia Li, Sudha Sadasivan, Ruicong She, Indrani Datta, Dhananjay Chitale, Nilesh Gupta, Melissa B. Davis, Craig G. Rogers, Lisa A. Newman, Pamela L. Paris, Benjamin A. Rybicki, Albert M. Levin


Paris Research Interests: My background is in biophysical chemistry. My research focuses on biomarker discovery. As a UCSF Prostate SPORE program Research Fellow, I discovered a DNA-based biomarker set to assess risk of recurrence after primary treatment. My landmark paper in the American Journal of Pathology set the stage for the use of formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue with microarrays for copy-number assessment. I was the first to demonstrate FFPE prostate biopsy tissue could be profiled on high-resolution microarrays. As Professor, I work as a translational researcher in prostate cancer, both in solid tumor and circulating biomarkers. I helped move the circulating tumor cell (CTC) field beyond enumeration and was the first to genomically profile prostate cancer CTCs. Recently, I have applied similar approaches to identify clinically relevant bladder cancer biomarkers. My research goal is to identify predictive and prognostic biomarkers to aid in clinical cancer decision-making.

http://urology.ucsf.edu/research/cancer/cancer-research-programs/paris-laboratory

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Breast cancer characteristics and survival among different Indigenous American communities in Peru

Authors*: Lizeth I. Tamayo, Tatiana Vidaurre, Jeannie Navarro Vásquez, Sandro Casavilca, Jessica I. Aramburu, Monica Calderon, Daniel Cherry, Sikai Song, Garth H. Rauscher, Laura Fejerman

Abstract #: 4240Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/5388Presentation Date/Time:April 17, 2018, 1:00 PM - 5:00 PMLocation: Section 11Presentation: Poster Session



_______________________________________________________________________

Neighborhood data system to enable health disparities research in Chicago

Authors*: David J. Press, Scarlett Lin Gomez, Briseis Aschebrook-Kilfoy, Habibul Ahsan

Abstract #: 4251 Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/5399Presentation Date/Time: April 17, 2018, 1:00 PM - 5:00 PMLocation: Section 11Presentation: Poster Session

Gomez Research Interests: Dr. Scarlett Lin Gomez is an epidemiologist with research interests in the role of social determinants of health, including race/ethnicity, socioeconomic status, gender, immigration status, sociocultural factors, and neighborhood contextual characteristics, on health outcomes. She is also Director of the Greater Bay Area Cancer Registry, a part of the California Cancer Registry and the NCI Surveillance Epidemiology End Results (SEER) Program. She has contributed surveillance data regarding cancer incidence and outcome patterns and trends for distinct Asian American, Native Hawaiian, and Pacific Islander and Hispanic ethnic groups, as well as cancer patterns by nativity status and neighborhood characteristics. She developed the California Neighborhoods Data System, a compilation of small-area level data on social and built environment characteristics, and has used these data in more than a dozen funded studies to evaluate the impact of social and built neighborhood environment factors on disease outcomes.

http://cancer.ucsf.edu/people/profiles/gomez_scarlett.8510

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Somatic MAPK pathway mutations are associated with high mutational burden and good survival in head and neck squamous cell carcinoma (HNSCC)

Authors*: Hoi-Lam Ngan, Andrew Y. Fong, Sharon Chan, Shing Chun Yu, Laura R. H. Ip, Jennifer R. Grandis, Vivian Lui

Abstract #: 4278Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/3297Presentation Date/Time: April 17, 2018, 1:00 PM - 5:00 PMLocation:Section 13Presentation: Poster Session



_______________________________________________________________________

Negative regulation of oncogenes by a novel tumor suppressor microRNA in prostate cancer

Authors*: Nadeem Bhat, Altaf A. Dar, Sharanjot Saini, Varahram Shahryari, Priyanka Kulkarni, Pritha Dasgupta, Soichiro Yamamura, Yuichiro Tanaka, Taku Kato, Yutaka Hashimoto, Marisa Shiina, Z. Laura Tabatabai, Guoren Deng, Rajvir Dahiya, Shahana Majid


Majid Research Interests: The Majid lab, located Urology Research Center at the VAMC/UCSF, focuses in the area of urological cancers to understand the etiology and to develop novel molecular biomarkers for initiation, progression and metastasis with special emphasis on prostate cancer. We have been working in the field of microRNAs, genetics and epigenetics of urologic cancers. Cancer progression markers are identified by employing genome-wide approaches, and utilizing cells culture and mouse models as well as tissues from patients. The objective of the lab is to identify novel therapeutic targets or valuable biomarkers to establish rational therapeutic strategies for the diagnosis and treatment of cancer.

http://profiles.ucsf.edu/shahana.majid

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Identification of novel combinatorial synthetic lethal vulnerabilities in KRAS-driven lung cancer

Authors*: Kaja Kostyrko, Marcus R. Kelly, Kyuho Han, Edwin E. Jeng, David W. Morgens, Michael C. Bassik, Peter K. Jackson, Alejandro Sweet-Cordero




_______________________________________________________________________

Genistein regulates non-coding RNA HOTAIR and epithelial-to-mesenchyme transition in renal cancer cells

Authors*: Mitsuho I. Sumida, Yuichiro Tanaka, Rajvir Dahiya, Soichiro Yamamura

Abstract #: 4430Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/5957Presentation Date/Time:April 17, 2018, 1:00 PM - 5:00 PMLocation: Section 20Presentation: Poster Session

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Increased NTF2 levels in melanoma cell lines affect nuclear size and cancer cell characteristics

Authors*: Lidija D. Vukovic, Bradley A. Stohr, Dan L. Levy


Stohr Research Interests: The research in my laboratory focuses on the telomere biology of human cancers. Telomeres are nucleoprotein structures that protect the ends of linear chromosomes. Telomeres shorten with each cell division, ultimately resulting in deprotection of the chromosome ends. Telomeric deprotection serves a tumor-suppressive function by initiating senescence and/or apoptosis in inappropriately dividing cells. However, deprotected telomeres frequently fuse together, resulting in genome instability that can promote tumorigenesis. The cellular context determines whether it is the tumor-suppressive or tumor-promoting role of the dysfunctional telomere that predominates. The long-term goal of my laboratory is to understand how different types of telomere dysfunction provoke these diverse cellular responses. This knowledge will provide insight into the origins and progression of human cancers and suggest novel strategies for telomere-based therapeutic approaches.

http://labmed.ucsf.edu/about/faculty/pathology-bstohr.html

_______________________________________________________________________

Lgr5 mediates positive B-cell selection and is critical for initiation and survival of B-cell malignancies

Authors*: K. Cosgun, A. Hecht, X. Yang, M. Mangolini, A. Aghajanirefah, G. Xiao, T. Sadras, Z. Chen, L. Klemm, H. Geng, C. Hong, Q. Song, D. Zeng, H. Jumaa5, D. Zeng, H. Clevers, M. Muschen

Abstract #: 4515Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/4361 Presentation Date/Time: April 17, 2018, 1:00 PM - 5:00 PMLocation: Section 23Presentation: Poster Session



_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Single-cell discrimination of altered human T cell states in the bladder tumor microenvironment

Authors*: David Yoonsuk Oh, Serena S. Kwek, Serghei Mangul, Siddharth S. Raju, Sasha Targ, Arun Burra, Eric Chow, Dvir Aran, Sima Porten, Maxwell V. Meng, Terence W. Friedlander, Chun Jimmie Ye, Lawrence Fong


Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of solid malignancies. We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy.

http://hemonc.ucsf.edu/fonglab/

_______________________________________________________________________

The oxygen carrier omx restores antitumor immunity and cures tumors as a single agent or in combination with checkpoint inhibitors in an intracranial glioblastoma mouse model

Authors*: Natacha Le Moan, Philberta Leung, Sarah Ng, Tina Davis, Carol Liang, Jonathan Winger, Stephen P. L. Cary, Nicholas Butowski, Ana Krtolica

Abstract #: 4726AAbstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/10121Presentation Date/Time: April 17, 2018, 1:00 PM - 5:00 PMLocation: Section 33Presentation: Poster Session

Butowski Research Interests: My research includes translational research and a wide range of clinical trials, including those with convection-enhanced delivery (CED) with real-time MRI imaging, targeted agents, immunotherapy, and combination strategies. I am the Director of Translational Research in Neuro-Oncology and lead the translational effort on behalf of the UCSF Brain Tumor Research Center and Preclinical Core. My work has helped to create the groundwork for allied research in neuro-oncology and an extensive UCSF clinical trial portfolio for patients with primary brain and spine tumors, including an assortment of immunotherapy trials and surgically based trials. I have also designed investigator initiated trials, including a clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with a range of novel targets, molecular markers and imaging biomarkers. I have also authored a number of peer-reviewed papers and presented work at national and international meetings.

https://www.ucsfhealth.org/nicholas.butowski

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Regional strategies for expanding the evolving continuum of Physical Sciences-Oncology Network (PS-ON) research advocacy experiences

Authors*: Susan Samson, Nastaran Zahir, Sheila M. Judge, Stuart Cornew, Bob Riter, Jeri Francoeur, Anne Meyn, Laurie Cynkin, Jason J. Northey, Valerie M. Weaver, Carole Baas




_______________________________________________________________________

Development and mechanistic characterization of USP7 deubiquitinase inhibitors

Authors*: Ingrid Wertz, Lorna Kategaya, Paola Di Lello, Lionel Rouge, Richard Pastor, Kevin R. Clark, Jason Drummond, Tracy Kleinheinz, Eva Lin, John-Paul Upton, Sumit Prakash, Johanna Heideker, Mark McCleland, Maria Stella Ritorto, Dario R. Alessi, Matthias Trost, Travis W. Bainbridge, Michael C. Kwok, Taylur P. Ma, Zachary Stiffler, Bradley Brasher, Yinyan Tang, Priya Jaishanker, Brian Hearn, Adam R. Renslo, Michelle R. Arkin, Frederick Cohen, Kebing Yu,Frank Peale, Florian Gnad, Matthew T. Chang, Christiaan Klijn, Elizabeth Blackwood, Scott E. Martin, William F. Forrest, James A. Ernst, Chudi Ndubaku, Xiaojing Wang, Maureen H. Beresini, Vickie Tsui, Carsten Schwerdtfeger, Robert A. Blake, Jeremy Murray, Till Maurer

Abstract #: SY23-03Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/404Presentation Date/Time: April 17, 2018, 11:35 AM - 12:00 PMLocation: Room S504 - McCormick Place South (Level 5)Presentation: Major Symposium

Arkin Research Interests: Our lab has been interested in drug discovery and chemical biology for ‘challenging’ cancer targets, including protein-protein interactions, allosteric enzymes, and proteases. Our tools include high-throughput screening, fragment-based drug discovery, and high-content imaging. Our long-term aim is to develop context-specific modulators and cysteine-reactive inhibitors to interrogate protein-interaction networks and develop innovative new medicines.

https://pharm.ucsf.edu/arkin

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Minorities in Cancer Research Scientific Symposium: Population-Specific Research on Cancer Targeted Treatments and Drug Response-- Contributing to the Elimination of Cancer Health Disparities – Chairperson


Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/9389Presentation Date/Time: April 17, 2018, 10:30 AM - 12:30 PMLocation: Room S106 - McCormick Place South (Level 1)Presentation: Major Symposium



_______________________________________________________________________

Cross-presenting DC in the TME

Authors*: Matthew F. Krummel

Abstract #: SY18-03 Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/1080Presentation Date/Time: April 17, 2018, 11:35 AM - 12:00 PMLocation: Room N427 - McCormick Place North (Level 4)Presentation: Major Symposium

Krummel Research Interests: The Krummel Lab focuses on understanding patterns of immune cell-cell interactions and how these generate “the immune system”. Over the past ten years, they have developed novel imaging technologies & computational platforms to understand immunological processes in space and in time within normal and diseased organs. They were the first to live-image events in progressive tumors and the lab is developing protein immuno-therapeutics using imaging to ‘guide’ this development. The lab also studies how T cells become activated. Activation involves a specialized ‘immune synapse’ formed between T cells and their antigen-presenting partner cells. The lab has also demonstrated how T cells signal through synapses while moving through organs and how T cells communicate with each other when they arrest. Recently, they have developed imaging technologies that allow observation of the immune system in the homeostatic, infected/injured, allergic or metastatic lung.

http://pathology.ucsf.edu/krummel/

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


Driver lessons from studies of brain tumor evolution

Authors*: Joseph F. Costello

Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/542Presentation Date/Time: April 17, 2018, 2:15 PM - 2:40 PMPMLocation: Room W196 - McCormick Place West (Level 1)Presentation: Major Symposium

Costello Research Interests: The Costello lab seeks to understand the full life history of human tumors, from the first mutation and epimutation through clonal selection and tumor recurrence. We use next-generation sequencing to discover patterns and interdependencies of genetic mutations, epigenetic alterations and gene expression changes. Current projects incorporate MRI guided tumor biopsies and treatment data with longitudinal genomics to allow the reconstruction of tumor evolution in the context of the human tumor in vivo. We are exploring the application of immune therapies to target tumor specific mutations in tumors that emerge as hypermutated following chemotherapy. On the gene level, we recently discovered the mechanism by which mutations in the TERT gene promoter leads to telomerase activation and are pursuing further mechanistic and therapeutic studies aimed at reversing tumor cell immortalization.

https://costellolab.ucsf.edu

_______________________________________________________________________

Genetic and genomic approaches for distinguishing latent from potentially aggressive prostate cancers

Authors*: John S. Witte

Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/741Presentation Date/Time: April 17, 2018, 1:35 PM - 2:00 PMLocation:Room S103 - McCormick Place South (Level 1)Presentation: Major Symposium



_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


State Specific Small Molecule Ligands for K-Ras

Authors*: Kevan Michael Shokat

Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/556Presentation Date/Time: April 17, 2018, 2:05 PM - 2:30 PMLocation: Room N227 - McCormick Place North (Level 2)Presentation: Major Symposium

Shokat Research Interests: My lab focuses on discovery of new chemical tools to decipher cellular signaling networks, particularly protein kinases and GTPases. Analysis of signal transduction pathways is challenging using traditional tools. Biochemical approaches have limited utility since signaling networks span from the cell surface to the nucleus, confounding reconstitution efforts. Genetic approaches allow specific perturbations, yet can be confounded by the emergent properties of signaling cascades. Chemical and pharmacological approaches enable rapid, reversible & graded inactivation of single components, but highly selective chemical probes are difficult to develop. My lab has solved this problem for protein kinases with a strategy based on a combination of protein engineering and organic synthesis.

http://shokatlab.ucsf.edu

_______________________________________________________________________

Effect of JAK/STAT or PI3Kδ plus PD-1 inhibition on the tumor microenvironment: Biomarker results from a phase Ib study in patients with advanced solid tumors

Authors*: John M. Kirkwood, Nicholas Iannotti, Daniel Cho, Steven O’Day, Geoffrey Gibney, F. Stephen Hodi,Pamela Munster, Paul Hoyle, Sherry Owens, Michael Smith, Niharika Mettu

Abstract #: CT176 Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/11152Presentation Date/Time: April 17, 2018, 2:45 PM - 5:00 PMLocation:N Hall C - McCormick Place North (Level 1)Presentation: Clinical Trials

Munster Research Interests: Our lab is interested in developing novel strategies to overcome hormone therapy resistance in breast cancer.

http://cancer.ucsf.edu/people/profiles/munster_pamela.3449

_______________________________________________________________________

TU

ES

DA

Y

| A

PR

IL 1

7, 2

018


MICR-MEG Joint Symposium: Aggressive Cancer Phenotypes in Racial/Ethnic Minority Populations: Opportunities and Challenges – Chairperson


Abstract #: Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/10271Presentation Date/Time: April 17, 2018, 3:00 PM - 5:00 PMLocation: Room N228 - McCormick Place North (Level 2)Presentation: Major Symposium



_______________________________________________________________________

Mission Bio: A New Era in Single-Cell Genomics and Precision Medicine

Authors*: Catherine C. Smith

Abstract #: ESP23Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/10360Presentation Date/Time: April 17, 2018, 3:00 PM - 4:00 PMLocation: Exhibitor Spotlight Theater B - Hall A - McCormick Place South (Level 3)Presentation: Exhibitor Spotlight

Smith Research Interests: My laboratory focuses on identification of therapeutic resistance mechanisms and novel treatment strategies for acute myeloid leukemia (AML). We have a particular emphasis on AML associated with mutations in Fms-like Tyrosine Kinase-3 (FLT3). FLT3 is mutated in ~30% of AML, with constitutively activating FLT3 internal tandem duplication (ITD) mutations conferring a poor prognosis. We employ a prototypical “bedside to bench and back” approach to the problem of cancer drug resistance, founded on the belief that the ultimate pathway to improved cancer therapy begins with translational studies that utilize samples from patients who have undergone therapy in real time. This strategy allows us to interrogate how tumors can evolve under the selective pressure of cancer therapy and allows us to devise ways to circumvent these evolutionary adaptations.

http://cancer.ucsf.edu/people/profiles/smith_catherine.3369

_______________________________________________________________________

*UCSF authors in bold

WE

DN

ES

DA

Y

| A

PR

IL 1

8,

201

8

58

Tumor metabolism and cognitive dysfunction in CNS lymphoma

Authors*: Lakshmi Subbaraj, Huimin Geng, Jigyasa Sharma, Marisa LaFontaine, James L. Rubenstein


Rubenstein Research Interests: The lab of Dr. James Rubenstein, Department of Medicine, works in the field immunotherapy and cancer. Their major interests are in the identification of genetic factors associated with relapse, in tumor cell tropism to the brain, and in defining the tumor microenvironment in order to improve the anti-tumor immune response. They are simultaneously involved in leading phase I and II trials in patients, in conducting correlative studies of the immune response in patients treated with immunotherapy, and in the development of novel preclinical models to understand disease mechanisms.

https://bms.ucsf.edu/directory/faculty/james-rubenstein-md-phd

_______________________________________________________________________

WEDNESDAY | APRIL 18, 2019

RAS and STAT5 pathway lesions are mutually exclusive in B-cell malignancies through mechanisms of biochemical cross-inhibition

Authors*: Lai N. Chan, Seyedmehdi Shojaee, Christian Hurtz, Rebecca Caeser, Gang Xiao, Huimin Geng, Steven Kornblau, Markus Muschen

Abstract #: 5469 Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/4443 Presentation Date/Time:April 18, 2018, 8:00 AM - 12:00 PMLocation: Section 20Presentation: Poster Session



_______________________________________________________________________


WE

DN

ES

DA

Y

| A

PR

IL 1

8,

201

8

59

Bi-allelic loss of CDKN2A initiates melanoma invasion and metastasis via E2F1-BRN2 axis

Authors*: Hanlin Zeng, Aparna Jorapur, A. Hunter Shain, Ursula E. Lang, Rodrigo Torres, Yuntian Zhang, Thomas Botton, Jue Lin, Andrew S. Mcneal, Matthew Donne, Ingmar N. Bastian1, Jeffrey P. North, Laura Pincus, Richard Yu, Beth S. Ruben, Nancy Joseph, Iwei Ye, Boris C. Bastian, Robert L. Judson

Abstract #: 5518Presentation Date/Time: April 18, 2018, 8:00 AM - 12:00 PMLocation: Section 22Presentation: Poster Session

_______________________________________________________________________

Oncogenic RTK signaling inhibits Spred1/NF1 to sustain constitutive Ras/MAPK signaling

Authors*: Evan Markegard, Ellen L. Mercado, Pau Castel, Jillian Silva, Jacqueline Galeas, Kathy Li, Anatoly Urisman, Frank McCormick


_______________________________________________________________________

Mapping signaling networks in Nf1 mutant tumors

Authors*: Daniela Pucciarelli, Ganesh Krishnamurthi, Steve Braunstein, Jean L. Nakamura


Nakamura Research Interests: The first area we study is Neurofibromatosis I (NF1), which is a genetic syndrome that can lead to tumors in children. Individuals with NF1 can develop brain tumors and tumors along their spines (as well as cancers in other organs). This is an incurable disease that can lead to many complications and even death. We have developed an experimental systems to study how mutations causing this disease actually lead to tumor formation, with the goal of using this information to develop better therapies. A second area of research is trying to understand why second cancers develop in some childhood cancer survivors. We analyze these second cancers from childhood cancer survivors (some of whom are now adults) for problems in the genetic code. By studying the abnormalities in the genetic code of second cancers, we expect to understand the biological processes leading to second cancers, and one day prevent these complications .

https://radonc.ucsf.edu/jean-nakamura

_______________________________________________________________________


WE

DN

ES

DA

Y

| A

PR

IL 1

8,

201

8

60

Genomic and expression profiling reveals molecular heterogeneity of disseminated tumor cells in early breast cancer

Authors*: Mark Jesus M. Magbanua, Hope Rugo, Louai Hauranieh, Ritu Roy, Janet Scott, Jen Chieh Lee, Feng Hsiao, Eduardo Sosa, Denise Wolf, Laura van’t Veer, Laura Esserman, John Park

Abstract #: 5578Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/2883 Presentation Date/Time:April 18, 2018, 8:00 AM - 12:00 PMLocation: Section 26Presentation: Poster Session

_______________________________________________________________________

Sequencing and cloning IDH1 R132H-targeted monoclonal T cell receptors from CD4+ T cells facilitated by opto-electric-positioning technology

Authors*: Duane Smith, Payal Watchmaker, Guido Stadler, Natalie Marks, Yelena Bronevetsky, Keviin Chapman, Hideho Okada

Abstract #: 5773Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/3527Presentation Date/Time: April 18, 2018, 8:00 AM - 12:00 PMLocation:Section 35Presentation: Poster Session

Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on development of novel immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. His lab was also the first to identify and fully characterized cytotoxic T-lymphocyte epitopes for gliomas. Dr. Okada has also delineated the role of an integrin receptor very late activation antigen-4 and chemokine CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these findings to develop a number of vaccine trials in both adult and pediatric glioma patients. More recently, his group developed a novel chimeric antigen receptor targeting glioblastoma cells, and are currently conducting a pilot trial.

http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html

_______________________________________________________________________


WE

DN

ES

DA

Y

| A

PR

IL 1

8,

201

8

61

Clinico-genomic analysis of temozolomide-induced hypermutation in both molecular subtypes of IDH-mutant glioma

Authors*: Matthew R. Grimmer

Abstract #: LB-376Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/10677Presentation Date/Time: April 18, 2018, 8:00 AM - 12:00 PMLocation: Section 45Presentation: Poster Session

Costello Research Interests: The Costello lab seeks to understand the full life history of human tumors, from the first mutation and epimutation through clonal selection and tumor recurrence. We use next-generation sequencing to discover patterns and interdependencies of genetic mutations, epigenetic alterations and gene expression changes. Current projects incorporate MRI guided tumor biopsies and treatment data with longitudinal genomics to allow the reconstruction of tumor evolution in the context of the human tumor in vivo. We are exploring the application of immune therapies to target tumor specific mutations in tumors that emerge as hypermutated following chemotherapy. On the gene level, we recently discovered the mechanism by which mutations in the TERT gene promoter leads to telomerase activation and are pursuing further mechanistic and therapeutic studies aimed at reversing tumor cell immortalization.

https://costellolab.ucsf.edu

_______________________________________________________________________

Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution

Authors*: A. Hunter Shain, Nancy M. Joseph, Richard Yu, Jamal Benhamida, Shanshan Liu, Tarl Prow, Beth Ruben, Jeffrey North, Laura Pincus, Iwei Yeh, Robert Judson, Boris C. Bastian

Abstract #: RADT06Abstract link: http://www.abstractsonline.com/pp8/#!/4562/presentation/10426Presentation Date/Time:April 18, 2018, 10:40 AM - 10:55 AMLocation: Room W196 - McCormick Place West (Level 1)Presentation: Recent Advances in Diagnostics and Therapeutics Research

62

Weiyun Ai, MD, PhD798 Pathway-directed high-throughput drug screen identifies PI3K inhibitors that synergistically potentiate antitumor activity of HDAC inhibitors in cutaneous T-cell lymphoma

Charalambos Andreadis, MD2957 Sequential transcriptomic and phosphorylation landscape of acute myelogenous leukemia (AML) on the single-cell level

Michelle Arkin, PhDSY23-03 Development and mechanistic characterization of USP7 deubiquitinase inhibitors

Alan Ashworth, PhD, FRS3371 Analysis of telomere length and dysfunction in normal breast tissue from BRCA2 mutation carriers

410 Genome-wide and focused CRISPR screens to study PARP inhibitor resistance mediated by mutations in PARP1

1225 Rare variants in DNA damage repair genes are associated with male breast cancer predisposition

1360 A PARylation biosensor genetic screen to identify novel PARylation targets

2986 E-cadherin/ROS1 inhibitor synthetic lethality inbreast cancer

Sourav Bandyopadhyay, PhD1957 Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

3297 A tyrosine kinase interactome reveals network states that guide the use of targeted therapies in cancer

Mary Helen Barcellos-Hoff, PhD2812 Status of TGFbeta signaling determines PARP inhibitor sensitivity in head and neck cancer

— Radiation Science and Medicine Working Group Town Hall Meeting and Networking Reception - Chairperson Elect

Boris C. Bastain, MD, PhDRADT06 Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution

SUMMARY OF ABSTRACTS BY FACULTY MEMBER

SU

MM

AR

Y O

F A

BS

TR

AC

TS

63

Spencer C. Behr, MD3694 Measuring oncogene signaling with transferrin-based PET: From bench to bedside

Trever G. Bivona, MD, PhD920 COP1 E3 ligase regulates response to oncogenic MAPK pathway inhibition

2325 Protein homeostasis adaptation to Hsp70 inhibition in cancer

3302 The molecular landscape of oncogenic signaling pathways in The Cancer Genome Atlas

3993 Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF

Nicholas Butowski, MD4726A The oxygen carrier omx restores antitumor immunity and cures tumors as a single agent or in combination with checkpoint inhibitors in an intracranial glioblastoma mouse model

Joseph F. Costello, PhD— Driver lessons from studies of brain tumor evolution

LB-376 Clinico-genomic analysis of temozolomide-induced hypermutation in both molecular subtypes of IDH-mutant glioma

Rajvir Dahiya, PhD471 High expression of miR-182 promotes prostate cancer aggressiveness in African-Americans compared to Caucasians

489 Up-regulation of miR-130b is involved in prostate cancer racial disparity thorough FHIT- β-catenin pathway inactivation

2457 Epithelial-to-mesenchymal transition and stemness: Key targets of HOTAIR-miR-203 interaction in renal cell carcinoma

2478 miR-182-5p suppresses progression of renal cancer through cell cycle arrest by targeting lncRNA MALAT-1

Laura J. Esserman, MD, MBA— Accelerating the Pace of Change by Incorporating Early End Point Into Care and Trials

961 Intralesional injection of anti-PD-1 (pembrolizumab) results in increased T cell infiltrate in high risk DCIS

Laura Fejerman, PhD— “Ethnicity,” nationality, genetic ancestry and breast cancer in women of Latin American origins

4240 Breast cancer characteristics and survival among different Indigenous American communities in Peru

— Minorities in Cancer Research Scientific Symposium: Population-Specific Research on Cancer Targeted Treatments and Drug Response-- Contributing to the Elimination of Cancer Health Disparities - Chairperson

— MICR-MEG Joint Symposium: Aggressive Cancer Phenotypes in Racial/Ethnic Minority Populations: Opportunities and Challenges - Chairperson

SU

MM

AR

Y O

F A

BS

TR

AC

TS

64

Felix Y. Feng, MD3218 Maternal embryonic leucine zipper kinase (MELK) confers radioresistance in triple-negative breast cancers (TNBC) through a nonhomologous end joining (NHEJ)-mediated pathway

Lawrence Fong, MD2981 Clonal deletion of tumor-specific T cells by combination checkpoint blockade compromises antitumor efficacy in low tumor burden states

4688 Single-cell discrimination of altered human T cell states in the bladder tumor microenvironment

Terence Friedlander, MDCT031 Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma

CT125 A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer

Huimin Geng, PhD368 B-lymphoid transcriptional repression of the pentose phosphate pathway reveals a unique therapeutic vulnerability of B cell malignancies

2983 CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignancies

4515 Lgr5 mediates positive B-cell selection and is critical for initiation and survival of B-cell malignancies

5469 RAS and STAT5 pathway lesions are mutually exclusive in B-cell malignancies through mechanisms of biochemical cross-inhibition

Jason Gestwicki, PhD2901 Identifying synthetic lethal interactions in castration-resistant prostate cancer using HSP40 and HSP70 inhibitors

Andrei Goga, MD, PhD1462 The oncogene MYC induces chromosomal instability through dysregulating mitotic progression evoking a dependency on TPX2

2398 Tumor cell-adipocyte gap junctions activate lipolysis in breast cancer

Scarlett Lin Gomez, MPH, PhD4251 Neighborhood data system to enable health disparities research in Chicago

Jennifer R. Grandis, MD1972 Targeting the IL-6 signaling pathway overcomes cetuximab resistance in head and neck squamous cell carcinoma

CT058 Molecular and clinical activity of CDX-3379, an anti-ErbB3 monoclonal antibody, in head and neck squamous cell carcinoma: A preoperative “window of opportunity” study

4278 Somatic MAPK pathway mutations are associated with high mutational burden and good survival in head and neck squamous cell carcinoma (HNSCC)

SU

MM

AR

Y O

F A

BS

TR

AC

TS

65

Robert L. Judson, PhD5518 Bi-allelic loss of CDKN2A initiates melanoma invasion and metastasis via E2F1-BRN2 axis

Natalia Jura, PhD1896 Patient-derived HER3 mutations transform ER+ and HER2+ breast cancer cells via MAPK pathway activation

Karla Kerlikowske, MD3226 Overweight and obese women with high volumetric breast density at high breast cancer risk

Nevan Krogan, PhD1317 Multi-scale mapping of the physical and functional architecture of the cancer cell

1381 Targeting histone acetyltransferases to reprogram high C-MYC expressing cancers

Matthew F. Krummel, PhDSY18-03 Cross-presenting DC in the TME

Shahana Majid, PhD1111 Role of a prometastatic miRNA as a negative regulator of the key metastasis suppressor genes in renal cell carcinoma

4292 Negative regulation of oncogenes by a novel tumor suppressor microRNA in prostate cancer

Frank McCormick, PhD, FRS, DSc (Hon)2842 The biological effects and therapeutic potential of directly targeting K-Ras

5520 Oncogenic RTK signaling inhibits Spred1/NF1 to sustain constitutive Ras/MAPK signaling

Sabine Mueller, MD, PhD900 Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG

Pamela Munster, MDCT176 Effect of JAK/STAT or PI3Kδ plus PD-1 inhibition on the tumor microenvironment: Biomarker results from a phase Ib study in patients with advanced solid tumors

Jean L. Nakamura, MD5526 Mapping signaling networks in Nf1 mutant tumors

Hideho Okada, MD, PhD5773 Sequencing and cloning IDH1 R132H-targeted monoclonal T cell receptors from CD4+ T cells facilitated by opto-electric-positioning technology

SU

MM

AR

Y O

F A

BS

TR

AC

TS

66

Pamela Paris, PhD4231 Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race-ethnicity

John W. Park, MD5578 Genomic and expression profiling reveals molecular heterogeneity of disseminated tumor cells in early breast cancer

Claudia Petritsch, PhD149 Tumor suppression by regulator of asymmetric cell division in glioma

Samuel J. Pleasure, MD, PhD1126 Exploring the roles of Suppressor of Fused in the postnatal neurogenic niche and tumorigenesis

Michael Prados, MD289 Probing the non-enhancing component of glioblastoma: Targeting what is left behind

Sabrina M. Ronen, PhD1431 Autophagic degradation of the endoplasmic reticulum leads to reduced phospholipid biosynthesis in mutant isocitrate dehydrogenase 1 gliomas

James L.Rubenstein, MD, PhD4975 Tumor metabolism and cognitive dysfunction in CNS lymphoma

Davide Ruggero, PhD— Translating the cancer genome one codon at a time and its therapeutic implications

Charles J. Ryan, MDLB-212 IMAAGEN study biomarker analysis in patients with long term response to abiraterone acetate with prednisone for non-metastatic castrate resistant prostate cancer

Sharanjot Saini, PhD525 Role of a novel microRNA gene at frequently deleted chromosome 8p region in prostate cancer

Licia Selleri, MD, PhD1966 A novel small-molecule compound targeting PBX1-DNA interaction impedes cancer cell survival and carboplatin resistance

SU

MM

AR

Y O

F A

BS

TR

AC

TS

67

Kevin Shannon, MD2063 SAMD9/SAMD9L mutations in familial monosomy 7

John A. Shepherd, PhD3260 Utilizing digital pathology to understand breast epithelial characteristics of benign breast disease among women undergoing diagnostic image-guided breast biopsy

3268 Associations of plasma trimethylamine N-oxide (TMAO), choline, and betaine with the gut microbiome and biomarkers of inflammation and cardiometabolic risk in the Multiethnic Cohort

Kevan M. Shokat, PhD— State Specific Small Molecule Ligands for K-Ras

Eric J. Small, MD2605 Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study

Catherine C. Smith, MD— Molecular Predictors of Response, Mediators of Resistance, Mechanisms of Action, Pharmacodynamic Markers, and Novel Disease Subsets - Chairperson

ESP23 Mission Bio: A New Era in Single-Cell Genomics and Precision Medicine

David Solomon, MD, PhD1558 STAG2 as a biomarker for prediction of recurrence in papillary non-muscle invasive bladder cancer

Matthew Spitzer, PhD— Defining New Immunotherapeutic Targets through Deep Molecular Characterization - Chairperson

Bradley A. Stohr, MD, PhD4456 Increased NTF2 levels in melanoma cell lines affect nuclear size and cancer cell characteristics

E. Alejandro Sweet-Cordero, MD543 IL-11, a novel diagnostic biomarker for lung adenocarcinoma, is involved in lung cancer tumorigenesis

2075 Whole genome sequence analysis informs precision medicine of pediatric cancers

2629 Genome-informed therapy for osteosarcoma

3918 Targeting the CLCF1-CNTFR signaling axis using directed evolution for lung cancer therapy

4362 Identification of novel combinatorial synthetic lethal vulnerabilities in KRAS-driven lung cancer

SU

MM

AR

Y O

F A

BS

TR

AC

TS

68

Yuichiro Tanaka, PhD1242 Differences of cytochrome P450 1B1 polymorphisms on prostate cancer risk between races

1404 Role of catechol-O-methyltransferase gene in prostate cancer

Osamu Tetsu, MD, PhD3104 Establishment of an oral tongue squamous cell carcinoma cell line from a never-smoking patient

Katherine Van Loon, MD, MPH— Colorectal cancer early diagnosis in low and middle income countries

Laura van ‘t Veer, PhD956 Systematic identification of the actionable kinase dependencies of chemotherapy-resistant triple-negative breast cancer

2611 Evaluation of ANG/TIE/hypoxia pathway genes and signatures as predictors of response to trebananib (AMG 386) in the neoadjuvant I-SPY 2 TRIAL for Stage II-III high-risk breast cancer

2612 BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY 2 breast cancer patients

Valerie M. Weaver, PhD— TME Chair: Opening remarks

1093 Epithelial-to-mesenchymal transition conveys resistance to restrictive growth conditions through increased autophagic flux

— Tissue mechanics modulates risk to malignancy

— Joint Cancer Immunology (CIMM) / Tumor Microenvironment (TME) Working Groups Evening Scientific Session - Closing Remarks

4767 Regional strategies for expanding the evolving continuum of Physical Sciences-Oncology Network (PS-ON) research advocacy experiences

Zena Werb, PhDLB-055 Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive, basal-like breast cancer

Joseph L. Wiemels, PhD222 Genome-wide association study of acute lymphoblastic leukemia in children with Down syndrome

3241 Children with acute lymphoblastic leukemia have increased arginase 2 at birth, implicating immunosuppression in leukemogenesis

John K. Weincke, PhD233 Evaluating glioma risk associated with extent of European admixture in African-Americans and Latinos

SU

MM

AR

Y O

F A

BS

TR

AC

TS

69

John S. Witte, PhD— Assessing the shared genetic basis of different cancers

2277 Machine learning to identify prostate cancer mutations for screening cell-free DNA (cfDNA)

2968 Imputation of the prostate cancer transcriptome in over 230,000 men reveals novel germline-somatic interaction mechanism of cancer risk

3669 Assessing the genetic heterogeneity of localized, multifocal prostate cancer via cell-free DNA

— Genetic and genomic approaches for distinguishing latent from potentially aggressive prostate cancers

Denise M. Wolf, PhD3287 An integrated TCGA pan-cancer clinical data resource to drive high quality survival outcome analytics

Soichiro Yamamura, PhD4430 Genistein regulates non-coding RNA HOTAIR and epithelial-to-mesenchyme transition in renal cancer cells

Elad Ziv, MD223 A meta-analysis of genome-wide association studies of multiple myeloma among African Americans

American Association for Cancer Research Annual...

Documents

Transcript of American Association for Cancer Research Annual...